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2.8 ELISA 
Whole splenic cells and whole eyes from all animals were collected, individually stored 
in liquid nitrogen, thawed, individually homogenized in 1.0 ml of phosphate‐buffered saline 
(PBS) containing a protease inhibitor cocktail (Sigma), and individually stored at ‐20C prior to 
performance of ELISA. At time of ELISA, homogenates were thawed, sonicated, clarified by cen‐
trifugation, and the resulting supernatants were subjected to ELISA for quantification of murine 
IL‐4, IL‐10, or IL17 protein using the commercially available kit provided by eBioscience (San Di‐
ego, CA) per manufacturer’s instructions. Total protein for each sample was determined using 
the Bradford Protein Assay (BioRad, Hercules, CA).  
 
2.9 Western blot analysis 
Whole spleens and whole eyes were collected from uninfected MAIDS ‐4, MAIDS‐8, and 
MAIDS‐10 animals, individually stored in liquid nitrogen, thawed, and individually homogenized 
in 1 ml of PBS containing protease inhibitor cocktail (Sigma). Standard Western blot analysis 
was performed for detection of IL‐17 and GAPDH proteins using rabbit‐anti‐human IL‐17 anti‐
body (1:200) (Santa Cruz Biotechnology) or rabbit‐anti‐mouse GAPDH antibody (1:3000) (Sigma) 
as primary antibodies, respectively. Following incubation with ImmunoPure goat anti‐rabbit IgG 
antibody (heavy plus light chains [H+L]) (1:5000) (Thermo Scientific) secondary antibody, the 
resulting nitrocellulose membrane (BioRad) was treated with chemiluminescence (ECL) West‐
ern blot detection reagents (GE Healthcare, Piscataway, NJ) and exposed to BioMax light film 
(Kodak, Rochester, NY). 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2.10 Histopathology 
Whole eyes collected from all animals were immediately fixed in 10% buffered formalin 
(Electron Microscopy Sciences, Hartford, PA) for at least 48 hr at 4C, frozen in Optimal Cutting 
Temperature (OCT) medium (Thermo Scientific, Rochester, NY), cut into 8‐um sections using a 
Shandon Special Motorized Electronic Cryotome (Thermo Scientific), and sections were col‐
lected onto positively charged microscope slides (Thermo Scientific). Hematoxylin and eosin 
staining was performed as previously described (Dix et al., 1994) with minor modifications. Ocu‐
lar sections were scored for frequency and severity of retinitis using a scoring system estab‐
lished by us previously (Dix et al., 1994). 
  
2.11 Immunohistochemical staining of ocular tissues  
 Formalin‐fixed eyes were then frozen in O.C.T. medium (Thermo Scientific, Rochester, 
NY) and cut using a Shandon Special Motorized Electronic Cryotome (Thermo Scientific) into 8‐
µm sections that were placed onto positively charged microscope slides (Thermo Scientific). 
Immunohistochemical staining was performed by incubating slides with eye sections in 10 mM 
sodium citrate (Sigma Aldrich) for 10 min at room temperature followed by a 5‐min rinse with 
PBS (Cellgro) at room temperature. Immunohistochemical staining for IL‐17 in retinal tissues 
was accomplished by reacting slides with rehydrated eye sections with polyclonal rabbit anti‐
hIL‐17 IgG (1:50) (Santa Cruz Biotechnology, Santa Cruz, CA) or with polyclonal normal rabbit 
IgG (1:400) (control, Santa Cruz Biotechnology), processed using the rabbit ABC Staining System 
(Santa Cruz Biotechnology), and stained with Vector Red alkaline phosphatase substrate (Vec‐
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tastain ABC‐AP Kit, Vector Laboratories, Burlingame, CA). Slides were counterstained with DAPI 
(Vector Laboratories).  
Double immunohistochemical staining for the identification of IL‐17 producing retinal 
cells was accomplished by incubating rehydrated eye sections with rabbit‐anti‐hIL‐17 IgG (1:50) 
(Santa Cruz Biotechnology) and goat anti‐hRhodopsin IgG (1:200) for identification of rod cells 
(Santa Cruz Biotechnology) or goat anti‐hOpsinSW IgG for identification of cone cells (1:200) 
(Santa Cruz Biotechnology) at 4 °C overnight in a humidified atmosphere.  Following three 
washes for 5 min with PBS, retinal sections were reacted with secondary antibodies, donkey 
anti‐goat DyLight488 (1:300) (Jackson ImmunoResearch Laboratories INC, West Grove, PA) and 
chicken anti‐rabbit DyLight594 (Jackson ImmunoResearch Laboratories INC) and incubated in 
the dark at room temperature for 1 hr in a humidified atmosphere. Sections were washed three 
times with PBS, mounted with medium containing DAPI (Vector Laboratories).  All stained sec‐
tions were viewed at 200x or 400x magnification.    
 
2.12 Recovery and quantification of infectious MCMV 
Whole MCMV‐infected eyes were collected from wild‐type MAIDS‐8 mice, IL‐4 ‐/‐ 
MAIDS‐8 mice, and IL‐10 ‐/‐ MAIDS mice at 10 days after subretinal injection and individually 
stored in liquid nitrogen prior to processing. At time of quantitative plaque assay, individual 
eyes were thawed, individually homogenized on ice in 1.0 ml of cold Delbecco’s Minimal Essen‐
tial Medium (DMEM) (Cellgro, Manassas, VA), and clarified by centrifugation. Ten‐fold dilutions 
of the resulting supernatants were titered onto monolayers of mouse embryo fibroblast (MEF) 
cells in 6‐well plates, allowed to adsorb for 1‐hr at 37C in a humidified atmosphere of 5% CO2, 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overlaid with 1.0 ml DMEM, and incubated for 5 days at 37C in a humidified atmosphere of 5% 
CO2. Individual plaques were counted using an inverted light microscope, and results were ex‐
pressed as the number of PFU per ml per whole eye (PFU/ml/eye).  
 
2.13 Statistical analysis 
All quantitative data obtained from quantitative real‐time RT‐PCR assay and ELISA were 
expressed as means + standard error of mean (SEM) or standard deviation (SD), respectively. At 
least two independent experiments per performed for each study. Statistical analysis was per‐
formed using the Wilcoxon‐rank sum or Student T‐test. A p value of < 0.05 was considered sig‐
nificant. 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3 AIM 1:  TEST THE HYPOTHESIS THAT THE INCREASE IN CD4+ T CELL CYTOKINES IL‐4 OR IL‐
10  DOWNREGULATE CELLULAR IMMUNITY TO INCREASE SUSCEPTIBILITY TO 
EXPERIMENTAL MCMV RETINITIS IN MICE WITH MAIDS 
The data in this aim were published in Ophthalmology and Eye Diseases, 2012. 
3.1 Introduction 
IL‐4 and IL‐10 are key Th2 cytokines whose production is stimulated systemically during 
AIDS (and therefore during AIDS‐related HCMV retinitis) as a result of HIV‐induced Th2 domi‐
nance. IL‐4 is an immunomodulatory Th2 cytokine that promotes a number of diverse immu‐
nological functions through binding to its two‐chain receptor (IL4R) that is expressed on both 
immune and non‐immune cells (Brown and Hural, 1997; Keegan and Zamorano, 1998). Al‐
though the immunological outcome(s) of IL‐4 secretion varies remarkably depending on effec‐
tor cell, target cell, and the microenvironment in which IL‐4 is secreted (Brown and Hural, 1997; 
Chomarat and Banchereau, 1997, 1998), IL‐4 promotes a number of diverse immunological 
functions that impact macrophage differentiation, the differentiation of CD4+ T cells into Th2 
cells, and the inhibition of secretion of various inflammatory cytokines (Paul, 2008). In compari‐
son, IL‐10 is an anti‐inflammatory Th2 cytokine that inhibits the production of INF‐g as well as 
other Th1 cytokines (Ouyang et al., 2011; Paul, 2008), an accomplishment achieved through 
binding of IL‐10 to its two‐chain receptor composed of an alpha and beta subunit (Moore et al., 
2001; Ouyang et al., 2011).  
Of greater significance, however, are observations that CD8+ T‐cell‐mediated cytotoxicity 
is remarkably diminished at times of increased IL‐4 and/or IL‐10 production. For example, in‐
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creased IL‐4 production during HIV infection results in conversion of cytotoxic CD8+ T cells to 
CD8‐ T cells that also produce more IL‐4, further suppressing the Th1 response (Brown and 
Hural, 1997; Erard et al., 1994; Erard et al., 1993). HIV infection also results in IL‐10‐producing 
CD8+ T cells that exhibit reduced cytolytic activity to HIV as well as other viruses including 
HCMV (Elrefaei et al., 2007). Overexpression of IL‐4 in mice also results in increased Fas‐ligand 
(FasL) expression on T cells and a concomitant decrease in perforin production, an important 
observation that suggests that IL‐4 favors Fas/FasL‐mediated cytotoxicity over perforin‐
mediated cytotoxicity (Aung and Graham, 2000). Similar results have also been observed during 
overexpression of IL‐10 (Dace et al., 2009; Furukawa et al., 2008). Taken together, these find‐
ings suggest a pivotal association between increased IL‐4 and/or IL‐10 production during retro‐
virus‐induced immunosuppression and suppressed cellular immunity, especially cellular immu‐
nity involving perforin‐mediated cytotoxicity.  
Using our MAIDS model of MCMV retinitis, we demonstrated previously that loss of the 
perforin cytotoxic pathway is responsible for increased susceptibility to MCMV retinitis during 
MAIDS (Dix et al., 2003a), and this increased susceptibility can be reversed by immunotherapy 
with the Th1 cytokine IL‐2 (Dix et al., 1997b). Moreover, MCMV‐infected eyes of MAIDS animals 
susceptible to MCMV retinitis contain high amounts of IL‐4 (Dix and Cousins, 2003a). These ob‐
servations, coupled with those from other laboratories showing that either IL‐4 or IL‐10 favor 
the Fas/FasL cytotoxic pathway over the perforin cytotoxic pathway (Aung and Graham, 2000; 
Baschuk et al., 2007; Dace et al., 2009; Furukawa et al., 2008; Kienzle et al., 2002; Kienzle et al., 
2005; Oshima et al., 2007; Saito et al., 1999), lead to the attractive hypothesis that an increase 
in systemic production of IL‐4 or IL‐10 during retrovirus‐induced immunosuppression is respon‐
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sible for increased susceptibility to MCMV retinitis during MAIDS. To our surprise, however, this 
hypothesis proved to be incorrect since mice with MAIDS deficient in either IL‐4 or IL‐10 exhib‐
ited a frequency of retinitis, a severity of retinitis, and intraocular amounts of infectious virus 
equivalent to those found in wild‐type mice with MAIDS. 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3.2 Results 
3.2.1 Quantification of splenic IL‐4 and IL‐10 mRNA levels in wildtype C57BL/6 mice during 
progression of MAIDS  
Early work by Gazzinelli and colleagues (Gazzinelli et al., 1992; Morse et al., 1995) dem‐
onstrated that progression of MAIDS is associated with a shift in cytokine production by splenic 
CD4+ T cells from a Th1 profile to a Th2 profile as seen in HIV‐infected patients with AIDS 
(Clerici and Shearer, 1993), and this shift commences at ~3 weeks after retrovirus infection (Dix 
and Cousins, 2004a). Although we have shown previously that IL‐4 mRNA levels increase signifi‐
cantly within the ocular compartment of MCMV‐infected eyes of mice with MAIDS (Dix and 
Cousins, 2003a), we sought to confirm that our animals in the absence of MCMV infection also 
exhibit a systemic increase in Th2 cytokines during the progression of MAIDS, especially for the 
Th2 cytokines IL‐4 and IL‐10 that have been associated with dampening of cellular immunity 
(Aung and Graham, 2000; Baschuk et al., 2007; Dix et al., 2003a; Kienzle et al., 2002; Kienzle et 
al., 2005). Initial experiments using quantitative RT‐PCR assay were therefore performed to 
measure IL‐4 and IL‐10 mRNA levels within splenic cells collected from wild‐type C57BL/6 mice 
with MAIDS of 4‐weeks duration (MAIDS‐4), 8‐weeks duration (MAIDS‐8), and 10‐weeks dura‐
tion (MAIDS‐10), but without ocular MCMV infection. Results are shown in Fig. 3.1. Whereas 
splenic IL‐4 mRNA levels increased nearly 2‐fold in MAIDS‐4 and MAIDS‐8 animals, MAIDS‐10 
animals showed a significant 4‐fold increase in splenic IL‐4 mRNA levels (Fig 3.1A). In compari‐
son, splenic IL‐10 mRNA levels also increased during progression of MAIDS, but this increase 
was evident later in the course of MAIDS and far greater than that seen for splenic IL‐4 mRNA. 
Whereas no significant increase in IL‐10 mRNA was observed in splenic cells collected from 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MAIDS‐4 animals, splenic IL‐10 mRNA levels were ~4‐fold and ~17‐fold higher in MAIDS‐8 and 
MAIDS‐10 animals, respectively (Fig 3.1B). Thus, as expected (Dix and Cousins, 2003a; Dix et al., 
1994; Morse et al., 1995) , our mice with MAIDS did indeed exhibit increased systemic produc‐
tion of IL‐4 and IL‐10 mRNAs during progression of retrovirus‐induced immunosuppression as 
measured using splenic cells, although the increase in splenic IL‐10 mRNA levels was far greater 
than that of splenic IL‐4 mRNA levels. Nonetheless, a significant increase in systemic mRNA lev‐
els to both Th2 cytokines was observed during MAIDS‐8 and MAIDS‐10, times during the course 
of retrovirus‐induced immunosuppression when mice become susceptible to MCMV retinitis 
following subretinal infection (Dix and Cousins, 2003a; Dix et al., 1994). 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Figure 3.1. IL‐4 and IL‐10 mRNA levels in whole splenic cells during progression of MAIDS. A. 
IL‐4 mRNA levels in whole splenic cells during MAIDS progression versus healthy controls, p < 
0.05 (n = 5) Error bars = Standard Error of Mean (SEM) of three independent experiments. As‐
terisks indicate statistical significance. B. IL‐10 mRNA levels in whole splenic cells during MAIDS 
progression versus. healthy controls, p ≤ 0.03 (n = 5) Error bars = SEM of two independent ex‐
periments. Asterisks indicate statistical significance. 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3.2.2 Measurement of IL‐4 mRNA and protein levels in anti‐IL‐4 antibody treated MAIDS 
mice  
We first sought to determine if a reduction of IL‐4 during MAIDS would result in in‐
creased resistance to MCMV retinitis. Therefore, mice with MAIDS of 8‐weeks duration were 
treated with either mouse anti‐IL‐4 IgG1 or matched isotype control IgG (i.p.) on days ‐3, 0, +3, 
and +6 relative to subretinal injection of left eyes with MCMV (Atherton et al., 1991; Dix et al., 
1994) or subretinal mock‐injection of right eyes with maintenance media (control). On day 10 
after subretinal injection, whole splenic cells were collected and quantified for IL‐4 mRNA or 
protein levels using real‐time RT‐PCR assay or ELISA, respectively. Results are shown in the Fig‐
ure 3.2 A and B respectively. While anti‐IL‐4 antibody treatment protocol failed to reduce 
splenic IL‐4 mRNA production in MAIDS animals, splenic IL‐4 protein levels were reduced by 
~50%. 
 
3.2.3 Measurement of IL‐10 mRNA levels in anti‐IL‐4 antibody treated MAIDS mice 
We then wanted to confirm that reduction of IL‐4 through the use of anti‐IL‐4 antibody 
would not affect the transcription of other Th2 cytokines. Thus, we quantified the mRNA ex‐
pression levels of the Th2 cytokine IL‐10 in whole splenic cells of anti‐IL‐4 antibody treated 
MAIDS mice and matched MAIDS controls using real‐time RT‐PCR assay.  Anti‐IL‐4 antibody 
treatment of MAIDS mice did not alter IL‐10 mRNA levels when compared to control MAIDS 
animals (Fig. 3.2C). 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Figure 3.2. IL‐4 mRNA, IL‐4 protein levels, and IL‐10 mRNA in whole splenic cells of anti‐IL‐4 
antibody (Ab)‐treated MAIDS mice versus respective controls. A. IL‐4 mRNA levels in isotype‐
treated control vs. Ab‐treated p = 0.8053 (no statistical difference) (Wilcoxon Rank Sum test) (n 
= 5 mice/group) Error bars = Standard Error of Mean (SEM) of two experiments. B. IL‐4 protein 
levels of Ab‐treated vs. isotype‐treated control. p < 0.05 (Student T‐test) (n = 5 mice/group) Er‐
ror bar = Standard Deviation (SD) of two experiments. C. IL‐10 mRNA levels in Isotype‐treated 
control vs. Ab‐treated p = 0.864 (no statistical difference) (Wilcoxon Rank Sum test) (n = 5 
mice/group) Error bar = SEM of two independent experiments. Asterisks indicate statistical sig‐
nificance. 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3.2.4 Measurement of perforin, granzyme B and FasL mRNA levels in anti‐IL‐4 antibody 
treated MAIDS mice  
Since IL‐4 has been shown to inhibit perforin and granzyme B production and thereby 
favor the Fas/FasL cytotoxic pathway (Aung and Graham, 2000; Baschuk et al., 2007; Dix et al., 
2003a; Kienzle et al., 2002; Kienzle et al., 2005), we next determined the fate of mRNAs for per‐
forin and granzyme B as well as FasL mRNA following systemic reduction of IL‐4 protein during 
MAIDS‐related MCMV retinitis. Whole spleens were collected from anti‐IL‐4 antibody‐treated 
MAIDS mice and matched control mice at day 10 after subretinal MCMV injection and quanti‐
fied for these mRNAs by real‐time RT‐PCR assay. We did not detect a significant difference in 
perforin, granzyme B, or FasL mRNA production by splenic cells in anti‐IL‐4 antibody‐treated 
mice with MAIDS when compared with splenic cells of control animals following subretinal 
MCMV injection (Fig. 3.3 A, B, and C respectively). 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Figure 3.3. Perforin, Granzyme B, and FasL mRNA levels in whole splenic cells of anti‐IL‐4 an‐
tibody (Ab)‐treated MAIDS mice versus respective controls. A.  Perforin mRNA levels in Iso‐
type‐treated control vs. Ab‐treated MAIDS splenic cells, p = 0.751 (no statistical difference) 
(Wilcoxon Rank Sum test) (n = 5 mice/group) Error bar = SEM of two independent experiments. 
B.  Granzyme B mRNA levels in Isotype‐treated control vs. Ab‐treated MAIDS splenic cells, p = 
0.105 (no statistical difference) (Wilcoxon Rank Sum test) (n = 5 mice/group) Error bar = SEM of 
two independent experiments. C.  FasL mRNA levels in Isotype‐treated control vs. Ab‐treated 
MAIDS splenic cells, p = 0.695 (no statistical difference) (Wilcoxon Rank Sum test) (n = 5 
mice/group) Error bar = SEM of two independent experiments. Asterisks indicate statistical sig‐
nificance. 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3.2.5 Frequency and severity of MCMV Retinitis in anti‐IL‐4‐antibody treated MAIDS mice  
We then sought to determine if reduction of IL‐4 levels during MAIDS resulted in in‐
creased resistance to MCMV retinitis. Ten days after subretinal MCMV infection, whole eyes of 
anti‐IL‐4 antibody treated MAIDS mice and matched control MAIDS mice were collected and 
analyzed for frequency and severity of retinitis. Results are shown in Table. 3.1 and Figure 3.4. 
As expected, MCMV‐infected eyes of control mice with MAIDS exhibited a frequency of retinitis 
of 83% (Dix and Cousins, 2004a), and with an average severity score of 2.84. In comparison, 
MCMV‐infected eyes of anti‐IL‐4 antibody‐treated MAIDS animals remained susceptible to 
MCMV retinitis. While the frequency of retinitis in MCMV‐infected eyes of mice with MAIDS 
treated with neutralizing antibody to IL‐4 was reduced by ~30% and the severity of disease was 
reduced to 2.35 when compared with control animals, these reductions were not significant. 
 
Table 3.1. Frequency and severity of MCMV necrotizing retinitis in groups of mice with MAIDS 
at day 10 after subretinal MCMV injection. 
 
Group  Frequency of necrotizing 
retinitis (retinitis/total) 
Severity Score 
MAIDS Isotype Control  83% (5/6)  2.84 
MAIDS Anti‐IL‐4 Antibody 
Treated 
50% (3/6)  2.35 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Figure 3.4. Photomicrographs of anti‐IL‐4 antibody (Ab)‐treated MAIDS mice eyes and iso‐
type‐control mice eyes. Top panel: Photomicrographs of formalin‐fixed OCT‐embedded frozen 
sections of retina of mock‐infected eyes collected from control animals at 10 days following 
subretinal injection of maintenance medium (right eyes) showing normal retinal architecture. 
Bottom panel: Photomicrographs of formalin‐fixed OCT‐embedded frozen sections of retina of 
eyes at 10 days after subretinal MCMV injection (left eyes) showing full‐thickness retinal necro‐
sis. (hematoxylin & eosin; magnification X 200) 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3.2.6 Induction of MAIDS in mice deficient in IL‐4 or IL‐10 
Due to the unexpected results obtained utilizing anti‐IL‐4 antibody treatment in MAIDS 
mice, we employed a second experimental approach utilizing IL‐4 ‐/‐ and IL‐10 ‐/‐ to determine 
if systemic reduction of IL‐4 or IL‐10 might lead to increased resistance to MCMV retinitis during 
MAIDS as hypothesized. We first attempted to induce MAIDS in IL‐4 ‐/‐ mice and IL‐10 ‐/‐ mice. 
Since IL‐4 and IL‐10 gene‐deficient mice are not available, we elected to use for these studies IL‐
4 ‐/‐ and IL‐10 ‐/‐ mice that possess a targeted mutation of the IL‐4 gene or IL‐10 gene that re‐
sults in the production of truncated, non‐functional IL‐4 (Kuhn et al., 1991) or IL‐10 (Kuhn et al., 
1993) protein products. Groups of IL‐4 ‐/‐ and IL‐10 ‐/‐ mice were therefore infected with the 
immunosuppressive retrovirus mixture, LP‐BM5, housed for 8 weeks, and assessed for devel‐
opment of MAIDS using criteria established by us previously (Dix et al., 1994). All retrovirus‐
infected IL‐4 ‐/‐ and IL‐10 ‐/‐ mice exhibited physical and immunological features consistent 
with development of MAIDS, and were designated as IL‐4 ‐/‐ MAIDS‐8 mice and IL‐10 ‐/‐ MAIDS‐
8 mice.  
Additional studies were performed to confirm that splenic IL‐10 mRNA levels were not 
affected in IL‐4 ‐/‐ mice MAIDS‐8 following subretinal MCMV infection, and, conversely, splenic 
IL‐4 mRNA levels were not affected in IL‐10 ‐/‐ MAIDS‐8 mice following subretinal MCMV infec‐
tion. This was of interest since Green and coworkers (Green et al., 2008) noted that IL‐10 ‐/‐ 
mice infected with LP‐BM5 exhibited exaggerated disease development when compared with 
wild‐type LP‐BM5‐infected C57BL/6 mice, an outcome that might affect splenic IL‐4 mRNA pro‐
duction. Results are shown in Fig. 3.4. While equivalent amounts of IL‐10 mRNA levels were ob‐
served in splenic cells collected from wild‐type MAIDS‐8 mice and IL‐4 ‐/‐ MAIDS‐8 mice follow‐
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ing intraocular MCMV infection, IL‐10 protein levels were significantly increased in IL‐4‐/‐ 
MAIDS‐8 mice. In comparison, while splenic IL‐4 mRNA levels were reduced by ~50% in IL‐10 ‐/‐ 
MAIDS‐8 mice when compared with wild‐type MAIDS‐8 mice following intraocular MCMV infec‐
tion, nearly equivalent amounts of IL‐4 protein were found within splenic cells of both animal 
groups. 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Figure 3.5. IL‐10 mRNA and IL‐10 protein levels in whole splenic cells of IL‐4 ‐/‐ MAIDS‐8 mice 
versus respective controls and IL‐4 mRNA and IL‐4 protein levels in whole splenic cells of IL‐10 
‐/‐ MAIDS‐8 mice versus respective controls. A. IL‐10 mRNA levels in whole splenic cells wild‐
type MAIDS versus IL‐4‐/‐ MAIDS‐8 mice, p = 0.432  (n = 10) Error bars = SEM of two independ‐
ent experiments. B. IL‐10 protein levels in whole splenic cells of wild‐type MAIDS vs. IL‐4‐/‐ 
MAIDS‐8 mice, p ≤ 0.02 (n = 10) Error bars = Standard Deviation (SD) of two independent ex‐
periments. Asterisks indicate statistical significance. C. IL‐4 mRNA in whole splenic cells of wild‐
type MAIDS versus IL‐10‐/‐ MAIDS‐8 mice, p ≤ 0.04 (n = 5) Error bars = SEM of one experiment. 
Asterisks indicate statistical significance. D. IL‐4 protein in whole splenic cells of wild‐type 
MAIDS versus IL‐10‐/‐ MAIDS‐8 mice p = 0.939 (n = 8, wild‐type MAIDS‐8 mice; n = 10, IL‐10‐/‐ 
MAIDS‐8 mice) Error bars = SD of one experiment. 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3.2.7 Quantification of amounts of infectious MCMV within eyes of wildtype MAIDS‐8 mice, 
IL‐4 ‐/‐ MAIDS‐8 mice, and IL‐10 ‐/‐ MAIDS‐8 mice following subretinal MCMV infection 
We have shown previously that the amounts of infectious MCMV within the ocular 
compartments of mice with MAIDS increase remarkably during development of retinitis follow‐
ing subretinal MCMV injection (Dix and Cousins, 2003a; Dix and Cousins, 2004a; Dix et al., 
1994). Moreover, since increased IL‐4 and IL‐10 production would tend to delay virus clearance 
by dampening of CD8+ T‐cell cytotoxicity, we sought to determine if loss of IL‐4 or IL‐10 would 
affect virus replication during MAIDS. Eyes of IL‐4 ‐/‐ MAIDS‐8 mice, IL‐10 ‐/‐ mice, and wild‐
type MAIDS mice were therefore infected with MCMV by subretinal injection, collected 10 days 
later, and subjected to standard plaque assay for quantification and comparison of amounts of 
infectious virus. As shown in Fig. 3.5, equivalent amounts of infectious virus were found in 
MCMV‐infected eyes of IL‐4 ‐/‐ MAIDS‐8 mice, IL‐10 ‐/‐ MAIDS‐8 mice, and their respective wild‐
type MAIDS‐8 controls. Thus, systemic loss of IL‐4 or IL‐10 during MAIDS did not appear to im‐
pact virus replication significantly within the eye, either positively or negatively. 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Figure 3.6. Ocular MCMV titer in wild‐type MAIDS‐8 mice, IL4 ‐/‐ MAIDS‐8 mice, and IL‐10 ‐/‐ 
MAIDS‐8 mice. A. Average virus titer (expressed as PFU/eye/ml) in whole eyes of wild‐type 
MAIDS‐8 mice versus IL‐4‐/‐ MAIDS‐8 mice at 10 days after subretinal MCMV infection p = 0.658 
(n = 5) Error bars = SEM of one experiment. B. Average virus titer (expressed as PFU/eye/ml) in 
whole eyes of wild‐type MAIDS‐8 mice versus IL‐10 ‐/‐ MAIDS‐8 mice at 10 days after subretinal 
MCMV infection p = 0.800 (n = 4) Error bars = SEM of one experiment. 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3.2.8 Frequency and severity of MCMV retinitis in IL‐4 ‐/‐ MAIDS‐8 mice and IL‐10 ‐/‐ MAIDS‐
8 mice following subretinal MCMV infection 
Since systemic loss of IL‐4 or IL‐10 had no effect of the amount of virus within the eyes of 
MAIDS‐8 mice that have been shown previously by us to be susceptible to retinitis (Dix and 
Cousins, 2004a; Dix et al., 1994), we sought to determine whether systemic loss of IL‐4 or IL‐10 
would result in increased resistance to retinitis as hypothesized. In separate experiments, IL‐4 ‐
/‐ MAIDS‐8 mice, IL‐10 ‐/‐ MAIDS‐8 mice, and their respective wild‐type MAIDS‐8 controls were 
infected with MCMV by subretinal inoculation. Ten days later, all eyes were collected, analyzed 
histopathologically, and scored for frequency and severity of necrotizing retinitis using a scoring 
system described previously (Dix et al., 1994). Results are shown in Table 3.2, Figure 3.6, and 
Figure 3.7. As expected, MCMV‐infected eyes of wild‐type MAIDS‐8 control mice were indeed 
susceptible to retinitis as indicated by frequencies of retinitis of 78% and 100% in separate ex‐
periments (average = 89%). In sharp opposition to our hypothesis, however, MCMV‐infected 
eyes collected from IL‐4 ‐/‐ MAIDS‐8 mice and IL‐10 ‐/‐ MAIDS‐8 exhibited a frequency of retini‐
tis equivalent to that observed in control animals. Whereas 89% of MCMV‐infected eyes of IL‐4 
‐/‐ MAIDS‐8 mice showed retinitis, 85% of IL‐10 ‐/‐ MAIDS‐8 mice also showed retinitis. Al‐
though frequency of retinitis was unaffected in MAIDS animals with a systemic loss of IL‐4 or IL‐
10, it was possible that loss of these Th2 cytokines would result in a decrease in severity of reti‐
nal disease. This was not the case (Table 3.2). When scored for severity of retinitis (Dix et al., 
1994), a statistical difference was not observed when MCMV‐infected eyes of IL‐4 ‐/‐ MAIDS‐8 
mice or MCMV‐infected eyes of IL‐10 ‐/‐ MAIDS‐8 mice were compared with MCMV‐infected 
eyes of their respective controls. 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Table 3.2. Frequency and severity of MCMV necrotizing retinitis in wild‐type MAIDS‐8 mice, 
IL‐4‐/‐ MAIDS‐8 mice, and IL‐10‐/‐ MAIDS‐8 mice at day 10 after subretinal MCMV infection. 
  
Group  Frequency of 
Necrotizing retinitis 
(retinitis/total) 
Severity Score 
Wildtype MAIDS‐8  78% (7/9)  2.94 (n = 7) 
IL‐4 ‐/‐ MAIDS‐8  89% (8/9)  3.24 (n = 8) 
Wildtype MAIDS‐8  100% (4/4)  3.72 (n = 4) 
IL‐10 ‐/‐ MAIDS‐8  85% (6/7)  3.14 (n = 6) 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Figure 3.7. Photomicrographs of IL‐4 ‐/‐ MAIDS mice eyes and wild‐type MAIDS mice eyes. 
Top panel: Photomicrographs of formalin‐fixed OCT‐embedded frozen sections of retina of 
mock‐infected eyes collected from control animals at 10 days following subretinal injection of 
maintenance medium (right eyes) showing normal retinal architecture. Bottom panel: Photomi‐
crographs of formalin‐fixed OCT‐embedded frozen sections of retina of eyes at 10 days after 
subretinal MCMV injection (left eyes) showing full‐thickness retinal necrosis. (hematoxylin & 
eosin; magnification X 200) 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Figure 3.8. Photomicrographs of IL‐10 ‐/‐ MAIDS mice eyes and wild‐type MAIDS mice eyes. 
Top panel: Photomicrographs of formalin‐fixed OCT‐embedded frozen sections of retina of 
mock‐infected eyes collected from control animals at 10 days following subretinal injection of 
maintenance medium (right eyes) showing normal retinal architecture. Bottom panel: Photomi‐
crographs of formalin‐fixed OCT‐embedded frozen sections of retina of eyes at 10 days after 
subretinal MCMV injection (left eyes) showing full‐thickness retinal necrosis. (hematoxylin & 
eosin; magnification X 200) 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3.2.9 Quantification of splenic perforin, granzyme B, and FasL mRNA levels in IL‐4 ‐/‐ MAIDS‐
8 mice and IL‐10 ‐/‐ MAIDS‐8 mice following subretinal MCMV infection 
Since MCMV‐infected eyes of mice with MAIDS deficient in systemic IL‐4 or IL‐10 failed to show 
a decrease in frequency or severity of retinitis as predicted, we were interested in knowing the 
fate of mRNAs of key molecules involved in CD8+ T‐cell cytotoxicity in animals unable to pro‐
duce functional systemic IL‐4 or IL‐10. These included perforin and granzyme B mRNAs associ‐
ated with the perforin cytotoxic pathway (Paul, 2008) and FasL mRNA associated with the 
Fas/FasL cytotoxic pathway (Paul, 2008). This was accomplished by measurement of perforin, 
granzyme B, and FasL mRNAs originating from splenic cells collected from IL‐4 ‐/‐ MAIDS‐8 mice 
and IL‐10 ‐/‐ MAIDS‐8 mice following subretinal MCMV infection and comparing these amounts 
by quantitative RT‐PCR assay with those obtained from wild‐type MAIDS‐8 mice following 
subretinal MCMV infection. As shown in Fig. 3.8, amounts of splenic perforin and granzyme B 
mRNAs remained relatively unchanged in mice with MAIDS deficient in systemic IL‐4 or IL‐10 
production when compared with wild‐type MAIDS animals. Moreover, MAIDS mice deficient in 
systemic IL‐4 or IL‐10 production showed a significant increase in splenic FasL mRNA produc‐
tion, an unexpected finding. 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Figure 3.9. Perforin, granzyme B, and FasL mRNA levels in whole splenic cells of IL‐4 ‐/‐ 
MAIDS‐8 mice and IL‐10 ‐/‐ MAIDS‐8 mice versus respective controls. A. Perforin mRNA levels 
in splenic cells of wild‐type MAIDS‐8 mice versus IL‐4‐/‐ MAIDS‐8 mice; p = 0.780 (n = 5) Error 
bars = SEM of two independent experiments. B. Perforin mRNA levels in splenic cells of wild‐
type MAIDS‐8 mice versus IL‐10‐/‐ MAIDS‐8 mice; p = 0.49 (n = 5) Error bars = SEM on one ex‐
periment. C. Granzyme B mRNA levels in splenic cells of wild‐type MAIDS‐8 mice versus IL‐4‐/‐ 
MAIDS‐8 mice; p = 0.691 (n = 5) Error bars = SEM of two independent experiments. D. Gran‐
zyme B mRNA levels in splenic cells of wild‐type MAIDS‐8 versus IL‐10 ‐/‐ MAIDS‐8 mice; p = 
0.22 (n = 5) Error bars = SEM of one experiment.  E. FasL mRNA in splenic cells of wild‐type 
MAIDS‐8 mice versus IL‐4 ‐/‐ MAIDS‐8 mice; p ≤ 0.01 (n = 5) Error bars = SEM of two independ‐
ent experiments. F. FasL mRNA in splenic cells of wild‐type MAIDS‐8 mice versus IL‐10 ‐/‐ 
MAIDS‐8 mice; p ≤ 0.007  (n = 5) Error bars = SEM of one experiment. Asterisks indicate statisti‐
cal significance. 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4 AIM 2:  TEST THE HYPOTHESIS THAT INCREASED PRODUCTION OF IL‐17 FROM CD4+ TH17 
CELLS CONTRIBUTES TO THE PATHOGENESIS OF EXPERIMENTAL MCMV RETINITIS IN MICE 
WITH MAIDS 
4.1 Introduction 
A more recently recognized CD4+ Th cell subset, Th17 cells, secretes a unique set of cyto‐
kines that includes IL‐17A (IL‐17) as well as TNF‐α, IL‐22, and IL‐6 (Annunziato et al., 2010; 
Bettelli et al., 2007; Furuzawa‐Carballeda et al., 2007; Schmidt‐Weber et al., 2007). Differentia‐
tion of the Th17 linage is dependent upon the secretion of IL‐6 and TFG‐ß from APCs (Bettelli et 
al., 2007; Furuzawa‐Carballeda et al., 2007; Gaffen, 2009; Schmidt‐Weber et al., 2007); the 
Th17 lineage is stabilized by IL‐23 secretion from APCs (Bettelli et al., 2007; Furuzawa‐
Carballeda et al., 2007; Gaffen, 2009; Schmidt‐Weber et al., 2007). A pro‐inflammatory cyto‐
kine, IL‐17 functions by binding to its receptor, IL‐17RA, that is expressed on a wide range of 
cells (Annunziato et al., 2010; Weaver et al., 2007) and thereby stimulates a number of immune 
responses including the recruitment of macrophages and neutrophils (Annunziato et al., 2010; 
Stockinger et al., 2007; Weaver et al., 2007). Of significance, however, is that IL‐17 has been 
associated with cellular damage that occurs during autoimmune diseases including rheumatoid 
arthritis and multiple sclerosis (Annunziato et al., 2010; Furuzawa‐Carballeda et al., 2007; Korn 
et al., 2009; Lovett‐Racke et al., 2011). Recent work by Luger and colleagues (Luger and Caspi, 
2008; Luger et al., 2008) and others (Amadi‐Obi et al., 2007; Caspi, 2008; Peng et al., 2007) has 
also linked IL‐17 to uveitis, a leading cause of blindness in the United States (Caspi, 2010).   
Although Th17 cells have been implicated in the pathogenesis of various autoimmune 
diseases, the role of IL‐17 during HIV‐induced immunosuppression remains controversial. 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Brenchley and co‐workers (Brenchley et al., 2008) found that Th17 cells were lost in mucosa of 
the gastrointestinal tract of HIV‐infected patients, but remained intact in simian immunodefi‐
ciency virus‐infected sooty mangabey monkeys. In contrast, other studies have found that IL‐17 
secretion from Th17 cells was increased during HIV infection (Maek et al., 2007; Yue et al., 
2008). To more clearly elucidate the role of Th17 cells in HIV infection as well as the potential 
contribution(s) of IL‐17 to the pathogenesis of AIDS‐related HCMV retinitis, we performed a se‐
ries of studies to test the hypotheses that systemic IL‐17 is increased during retrovirus‐induced 
immunosuppression, and this systemic increase in IL‐17 production plays a role in the patho‐
genesis of cytomegalovirus retinitis within the ocular compartment.  
These hypotheses were tested using a mouse model of MCMV retinitis that develops in 
mice with MAIDS, a retrovirus‐induced immunodeficiency syndrome with features that closely 
mimic HIV/AIDS in humans (Dix and Cousins). Importantly, mice with MAIDS exhibit lymphade‐
nopathy, polyclonal B‐cell activation, hypergammaglobulinemia, and a retrovirus‐induced shift 
in cytokine production from a dominant Th1 response to a dominant Th2 response prior to sus‐
ceptibility to experimental MCMV retinitis (Dix and Cousins, 2004a; Dix et al., 1994; Morse et 
al., 1995), thereby making this an attractive animal model to investigate IL‐17 in the context of 
MCMV retinal disease development.  
We report herein that while IL‐17 mRNA and protein levels increased in mice with MAIDS, 
CD4+ T cells were not the sole source of IL‐17 during retrovirus‐induced immunosuppression 
progression. Surprisingly, however, IL‐17 mRNA and protein levels were dampened in MCMV‐
infected eyes of mice with MAIDS that were susceptible to retinitis, a result that was also ob‐
served following systemic MCMV infection of both healthy mice and MAIDS mice. Decreased 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levels of IL‐17 correlated with increased mRNA levels of IL‐10 and suppressor of cytokine signal‐
ing (SOCS)‐3 during MCMV infection. While systemic MCMV infection of healthy IL‐10 ‐/‐ mice 
resulted in a partial recovery of IL‐17 protein levels, IL‐10 ‐/‐ MAIDS animals remained suscepti‐
ble to MCMV retinitis at levels equivalent to wild‐type MAIDS mice. Taken together, our results 
suggest that IL‐17 plays no direct role in the pathogenesis of MAIDS‐related MCMV retinitis, but 
that MCMV downregulates IL‐17 from CD4+ T cells through the upregulation of IL‐10 and po‐
tentially SOCS‐3. 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4.2 Results 
4.2.1 IL‐17 protein production in whole splenic cells and whole eyes of healthy C57BL/6 mice     
We first sought to determine baseline levels of expression of IL‐17 protein in the spleens 
and eyes of C57BL/6 mice during health. Results are shown in Figure 1. Detectable amounts of 
IL‐17 protein were found in homogenates of whole splenic cells and whole eyes of healthy ani‐
mals by ELISA (Fig. 4.1A and Fig. 4.1B) as well as by Western blot analysis (data not shown). 
ELISA showed 4.73 + 1.84 pg of IL‐17 per gram of spleen (wet weight) and 0.87 + 0.31 pg of IL‐
17 per whole eye. Moreover, visualization of IL‐17 protein by immunohistochemical staining of 
the posterior segment of healthy whole eyes revealed constitutive expression of IL‐17 with an 
expression pattern confined to the photoreceptor and inner plexiform layers of the neurosen‐
sory retina (Fig. 4.1C). Thus, IL‐17 was not only produced within the spleen of healthy mice, but 
was also found to be expressed constitutively by cells of the neurosensory retina of healthy 
mice. Further analysis of the photoreceptor cells revealed that both rods and cones constitu‐
tively express IL‐17 during health (Fig 4.2). 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Figure 4.1. Detection and quantification of IL‐17 protein in whole splenic cells and whole eyes 
of healthy C57Bl/6 mice. (A) IL‐17 protein in whole splenic cells of adult healthy C57BL/6 mice 
as determined by ELISA [pg of IL‐17 per gram of spleen (wet weight] (n = 10). Bars = Standard 
Deviation of 1 experiment. (B) IL‐17 protein in whole eyes of adult healthy C57BL/6 mice as de‐
termined by ELISA [pg of IL‐17 per whole eyes] (n = 10). Bars = Standard Deviation of 1 experi‐
ment. (C) Detection of IL‐17 in cells of a representative retinal tissue section collected from an 
adult healthy mouse. Formalin‐fixed cytosections were reacted with anti‐IL‐17 antibody (red) or 
an isotype‐matched normal antibody (control). Nuclei were counterstained with DAPI (blue) 
(200X). 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Figure 4.2. Detection of IL‐17 protein in photoreceptor cells of healthy C57BL/6 mice. Forma‐
lin‐fixed cytosections were reacted with anti‐IL‐17 antibody (red) and anti‐OpsinSW antibody 
(green) or anti‐Rhodopsin antibody (green). Nuclei were counterstained with DAPI (blue) 
(400X). 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4.2.2 IL‐17 mRNA and protein production in whole splenic cells and whole eyes of C57BL/6 
mice during progression of MAIDS  
After establishing baseline levels of expression of IL‐17 in the spleen and eyes of healthy 
C57BL/6 mice, we next investigated possible changes in IL‐17 mRNA and protein production 
during the progression of MAIDS in order to clarify the fate of IL‐17 during retrovirus‐
immunosuppression. Whole splenic cells and whole eyes were collected from MAIDS‐4, MAIDS‐
8, and MAIDS‐10 mice and quantified for IL‐17 mRNA and protein levels by real‐time RT‐PCR 
assay and ELISA, respectively. Progression of MAIDS was associated with a significant (p ≤ 0.03) 
increase in IL‐17 mRNA levels in whole splenic cells, with the levels peaking in MAIDS‐10 ani‐
mals (Fig. 4.3A). This increase in IL‐17 transcript production was reflected in a significant (p ≤ 
0.001) increase in IL‐17 protein production in whole splenic cells during MAIDS progression, 
with protein levels being highest at 41.5 ± 6.1 and 23.5 ± 5.13 pg per gram of spleen (wet 
weight) in MAIDS‐8 and MAIDS‐10 animals, respectively (Fig. 4.3B).  
MAIDS progression was also associated with a significant (p ≤ 0.0006) increase in IL‐17 
mRNA levels in whole eyes of MAIDS‐8 and MAIDS‐10 animals (Fig. 4.3C), but ocular IL‐17 pro‐
tein levels in these animals did not differ from IL‐17 levels in the eyes of healthy mice (Figure 
4.3D). We postulate that this is due to the degradation of IL‐17 mRNA shortly after transcription 
or the storage of IL‐17 mRNA in cytoplasmic vesicles such that mRNA is ultimately not being 
translated into protein. It is noteworthy that previous work has shown MAIDS‐8 and MAIDS‐10 
animals are susceptible to MCMV retinitis (Dix and Cousins, 2004a; Dix et al., 1994). The ele‐
vated levels of IL‐17 mRNA and protein in whole splenic cells during the progression of MAIDS 
suggested that numbers of IL‐17‐producing Th17 cells may be increased during progression of 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retrovirus‐induced immunosuppression, but this increase may not necessarily be found within 
the ocular compartment. 
 
Figure 4.3. IL‐17 mRNA and protein levels in whole splenic cells and whole eyes of C57BL/6 
mice during the progression of MAIDS. Comparison of (A) IL‐17 mRNA levels of whole splenic 
cells collected from groups of MAIDS‐4, MAIDS‐8, and MAIDS‐10 mice (n = 5), and (C) IL‐17 
mRNA levels of whole eyes collected from groups of MAIDS‐4, MAIDS‐8, and MAIDS‐10 mice (n 
= 5). Levels (fold‐change) of IL‐17 mRNA were determined by quantitative RT‐PCR assay. Bars = 
Standard Error of the Mean of 3 independent experiments. Asterisks indicate statistical signifi‐
cance. Comparison of (B) IL‐17 protein levels of whole splenic cells collected from groups of 
MAIDS‐4, MAIDS‐8, and MAIDS‐10 mice (n = 5), and (D) IL‐17 protein levels of whole eyes col‐
lected from groups of MAIDS‐4, MAIDS‐8, and MAIDS‐10 mice (n = 5). Levels (fold‐change) of IL‐
17 mRNA were determined by quantitative RT‐PCR assay. Protein levels were determined by 
ELISA. Bars = Standard Deviation of 1 experiment. 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4.2.3 IL‐17 mRNA levels in enriched populations of splenic CD4+ T cells, splenic macro‐
phages, and splenic Gr‐1‐expressing cells (neutrophils) during progression of MAIDS   
We next sought to determine the cellular source of splenic IL‐17 production in MAIDS‐8 
and MAIDS‐10 animals. Known cellular sources of IL‐17 that included populations of splenic 
CD4+ T cells, splenic macrophages, and splenic Gr‐1‐expressing cells (neutrophils) (Gu et al., 
2008; Korn et al., 2009; Weaver et al., 2007) were enriched by flow cytometry (purity > 90%) 
from the whole spleens of MAIDS‐4, MAIDS‐8, and MAIDS‐10 mice and quantified for IL‐17 
mRNA levels by real‐time RT‐PCR assay. Unlike whole splenic cells, the progression of MAIDS 
was associated with a decrease in IL‐17 mRNA levels in splenic cells enriched for CD4+ T cells 
(Fig. 4.4). Purified splenic macrophages and splenic Gr‐1‐expressing cells (neutrophils) also ex‐
hibited similar yet significant (p ≤ 0.05) decreases in IL‐17 mRNA levels, and therefore contrib‐
uted little to overall expression of IL‐17 mRNA within the whole spleen (Fig. 4.4). Our finding of 
decreased IL‐17 mRNA from CD4+ T cells during MAIDS progression suggested that retrovirus‐
induced immunosuppression might alter essential Th17 cell differentiation factors including IL‐
23 and IL‐6. 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Figure 4.4. IL‐17 mRNA levels of enriched populations of splenic CD4+ T cells, splenic macro‐
phages, and splenic Gr‐1+ cells (neutrophils) from C57BL/6 mice during the progression of 
MAIDS. IL‐17 mRNA levels for enriched populations (> 90% purity) of splenic CD4+ T cells (gray 
bars), splenic macrophages (black bars), and splenic Gr‐1+ cells (neutrophils) (white bars) of 
whole splenic cells collected from groups of MAIDS‐4, MAIDS‐8, and MAIDS‐10 mice (n = 5). 
Levels (fold‐change) of IL‐17 mRNA were determined by quantitative RT‐PCR assay. Bars = Stan‐
dard Error of the Mean of 3 independent experiments. Asterisks indicate statistical significance. 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4.2.4 IL‐6 and IL‐23 mRNA production in whole splenic cells during progression of MAIDS 
IL‐6 and IL‐23 from APCs are required for the differentiation of the mouse Th17 lineage 
(Bettelli et al., 2007; Furuzawa‐Carballeda et al., 2007; Gaffen, 2009; Schmidt‐Weber et al., 
2007). In order to address the discrepancy that was seen in IL‐17 mRNA expression levels be‐
tween whole splenic cells and purified populations of splenic CD4+ T cells during MAIDS pro‐
gression, we measured IL‐6 and IL‐23 mRNA levels in order to determine whether these cytoki‐
nes were reduced at various times during retrovirus‐induced immunosuppression. Whole 
splenic cells collected from groups of MAIDS‐4, MAIDS‐8, and MAIDS‐10 mice exhibited IL‐6 and 
IL‐23 mRNA levels equivalent to mRNA levels seen in healthy age‐matched control mice (Fig. 
4.5). Thus, the decrease in IL‐17 mRNA production seen in CD4+ T cells during MAIDS progres‐
sion was not due to the unavailability of the essential linage factors IL‐6 or IL‐23. Our findings 
suggest that in addition to splenic CD4+ T cells, other cellular sources like CD8+ T cells or NKT 
cells contribute to the overall increase in IL‐17 production in whole splenic cells during MAIDS 
progression (Kondo et al., 2009; Rachitskaya et al., 2008). 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Figure 4.5. IL‐6 and IL‐23 mRNA levels of whole splenic cells from C57BL/6 mice during the 
progression of MAIDS. IL‐6 and IL‐23 mRNA levels of whole splenic cells collected from groups 
of MAIDS‐4, MAIDS‐8, and MAIDS‐10 mice (n = 5). Levels (fold‐change) of IL‐6 and IL‐23 mRNA 
were determined by quantitative RT‐PCR assay. Bars = Standard Error of the Mean of 3 inde‐
pendent experiments. Asterisks indicate statistical significance. 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4.2.5 IL‐17 mRNA levels in MCMV‐infected eyes of MAIDS‐4 mice resistant to retinitis and 
MCMV‐infected eyes of MAIDS‐10 mice susceptible to retinitis 
We next sought to determine whether the increased systemic levels of IL‐17 from whole 
splenic cells of MAIDS mice contributed to the pathogenesis of MCMV‐related retinitis. We 
have previously reported that while MCMV‐infected eyes of MAIDS‐4 and MCMV‐infected eyes 
of MAIDS‐10 mice have equivalent amounts of infectious virus at 10 days after subretinal 
MCMV infection, MAIDS‐4 animals are resistant to MCMV retinitis whereas MAIDS‐10 animals 
are susceptible to MCMV retinitis (Chien and Dix, 2012; Dix and Cousins, 2004b). Because 
MAIDS‐4 and MAIDS‐10 mice exhibit such divergent pathogenic outcomes following subretinal 
MCMV infection, we compared MCMV‐infected eyes of MAIDS‐4 and MCMV‐infected eyes of 
MAIDS‐10 mice for amounts of IL‐17 mRNA. Whole eyes were collected from parallel groups of 
MAIDS‐4 and MAIDS‐10 animals inoculated subretinally with MCMV or maintenance medium 
only (control), and analyzed on days 3, 6, and 10 post‐infection for amounts of IL‐17 mRNA. 
Subretinal MCMV infection of eyes of MAIDS‐4 mice did not result in increased IL‐17 mRNA lev‐
els when compared to mock‐infected eyes of MAIDS‐4 mice (Fig. 4.6A). In sharp contrast, 
MCMV‐infected eyes of MAIDS‐10 mice exhibited a significant (p ≤ 0.05) decrease in IL‐17 
mRNA levels on day 10 when compared to mock‐infected eyes of MAIDS‐10 mice (Fig. 4.6A).  
Due to the significant decrease in IL‐17 mRNA levels in MCMV‐infected eyes of MAIDS‐
10 mice, ELISA and immunohistochemical staining were also utilized to detect and quantify in‐
traocular IL‐17 protein in these animals. IL‐17 protein levels were decreased, although not sig‐
nificantly, when compared to contralateral mock‐infected eyes (data not shown). Immunohis‐
tochemical staining also revealed that IL‐17 protein was detectable in cells of the neurosensory 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retina and RPE of the eyes of both MCMV‐infected and mock‐infected MAIDS‐10 mice (Fig 
4.6B), but IL‐17 production in the MCMV‐infected eyes of MAIDS‐10 mice was dampened when 
compared to mock‐infected eyes. Taken together (Fig 4.6A and 4.6B), these unexpected results 
suggested that MCMV infection may downregulate IL‐17 production within the ocular com‐
partment during MAIDS. 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Figure 4.6. IL‐17 mRNA levels in MCMV‐infected eyes of MAIDS‐4 versus MAIDS‐10 mice and 
detection of IL‐17 protein in MCMV‐infected eyes of MAIDS‐10 mice. A) Comparison of IL‐17 
mRNA levels in MCMV‐infected eyes of MAIDS‐4 mice (blue dashed line) versus MCMV‐infected 
eyes of MAIDS‐10 mice (red solid line) collected at 3, 6, or 10 days after subretinal MCMV infec‐
tion (n = 5). Levels (fold‐change) of IL‐17 mRNA were determined by quantitative RT‐PCR assay. 
Bars = Standard Error of the Mean of 2 independent experiments. Asterisks indicate statistical 
significance. (B) Detection of IL‐17 in cells of representative retinal tissue sections collected 
from eyes of MAIDS‐10 mice at 10 days after subretinal MCMV infection or mock infection. 
Formalin‐fixed cytosections were reacted with anti‐IL‐17 antibody (red) or an isotype‐matched 
normal antibody (control). Nuclei were counterstained with DAPI (blue) (200X). 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4.2.6 Effect of systemic MCMV infection on IL‐17 mRNA levels in splenic CD4+ T cells during 
health and MAIDS 
The observation of significantly decreased IL‐17 mRNA levels and dampened protein 
levels in MCMV‐infected eyes of MAIDS‐10 mice led us to investigate the remarkable possibility 
that MCMV infection might lead to a preferential downregulation of IL‐17 from CD4+ Th17 cells 
systemically. To investigate this possibility, IL‐17 mRNA levels were quantified by real‐time RT‐
PCR assay in populations of splenic CD4+ T cells enriched by flow cytometry (purity > 90%) from 
groups of healthy, MAIDS‐4, or and MAIDS‐10 mice infected systemically by i.p. injection with a 
sublethal dose of MCMV for 6 days. Systemic MCMV infection of all animals resulted in a sig‐
nificant (p ≤ 0.01) decrease in IL‐17 mRNA levels in splenic CD4+ T cells when compared to 
mock‐infected controls (Figs. 4.7A and 4.7B). Whole splenic cell populations from all animal 
groups also exhibited a significant (p ≤ 0.008) decrease in IL‐17 mRNA levels (data not shown). 
Thus, systemic MCMV infection did indeed result in a significant downregulation of IL‐17 mRNA 
production from CD4+ T cells.  
In order to determine whether productive MCMV infection was required to downregu‐
late IL‐17 mRNA production in CD4+ T cells, groups of healthy, MAIDS‐4, or MAIDS‐10 mice 
were systemically inoculated with either UV‐inactivated MCMV or infectious MCMV for 6 days, 
and splenic CD4+ T cells enriched by flow cytometry (purity >90%) were analyzed for IL‐17 
mRNA expression via real‐time RT‐PCR assay. IL‐17 mRNA levels were significantly (p ≤ 0.05) re‐
duced in all animals inoculated with UV‐inactivated MCMV (Fig. 4.7C), but IL‐17 mRNA levels 
were further reduced when animals were inoculated with infectious MCMV (Fig. 4.7C). These 
results suggest that MCMV structural protein(s) (tegument proteins and/or glycoproteins) as 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well as one or more virus‐induced proteins produced during active virus replication alter the 
host cell response to decrease IL‐17 production during systemic MCMV infection.  
 
 
Figure 4.7. IL‐17 mRNA levels in splenic CD4+ T cells of healthy C57BL/6 mice, MAIDS‐4 mice, 
and MAIDS‐10 mice following systemic MCMV infection. IL‐17 mRNA levels of splenic CD4+ T 
cells collected from (A) groups of healthy C57BL/6 mice (n = 5) and (B) groups of MAIDS‐4 and 
MAIDS‐10 mice (n = 5) at 6 days after i.p. inoculation with MCMV or mock‐infection. Levels 
(fold‐change) of IL‐17 mRNA were determined by quantitative RT‐PCR assay. Bars = Standard 
Error of the Mean of 3 independent experiments. Asterisks indicate statistical significance. (C) 
IL‐17 mRNA levels of splenic CD4+ T cells collected from MAIDS‐4 mice, MAIDS‐10 mice, and 
their age‐matched healthy controls inoculated with either UV‐inactivated MCMV or infectious 
MCMV. Levels (fold‐change) of IL‐17 mRNA were determined by quantitative RT‐PCR assay. Bars 
= Standard Error of the Mean of 1 experiment. Asterisks indicate statistical significance. 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4.2.7 SOCS‐3, SOCS‐1, and IL‐10 mRNA expression levels in whole splenic cells of mice with 
MAIDS.  
We then sought to investigate the possible mechanism(s) by which IL‐17 mRNA was be‐
ing downregulated by CD4+ T cells during MAIDS progression and ultimately during MCMV in‐
fection. Previous studies conducted by Chen and colleagues (Chen et al., 2006) identified the 
SOCS‐3 protein as a negative regulator of IL‐17 in CD4+ T cells. Additionally, loss of the SOCS‐1 
protein leads to defective Th17 cell differentiation (Tanaka et al., 2008; Yoshimura et al., 2007). 
Ongoing work in our laboratory by Dr. Hsin Chien has also tied SOCS‐1 and SOCS‐3 to MCMV‐
related disease. Although both SOCS‐1 and SOCS‐3 are increased during HIV infection (Akhtar 
and Benveniste, 2011), we investigated whether SOCS‐3 mRNA levels were increased in mice 
with retrovirus‐induced immunosuppression and/or whether SOCS‐1 mRNA levels were de‐
creased, thereby leading to a decrease in IL‐17 expression from CD4+ T cells during MAIDS. 
Whole splenic cells collected from groups of MAIDS‐4, MAIDS‐8, or MAIDS‐10 mice were quan‐
tified for SOCS‐1 and SOCS‐3 mRNA levels by real‐time RT‐PCR assay. Whereas splenic mRNA 
levels of SOCS‐1 in MAIDS animals remained equivalent to mRNA levels of healthy mice (Fig. 
4.8A), SOCS‐3 mRNA levels were significantly (p ≤ 0.05) increased during MAIDS progression 
(Fig. 4.8B). Importantly, increased SOCS‐3 mRNA levels correlated with decreased IL‐17 mRNA 
levels in splenic CD4+ T cells seen during MAIDS progression (Fig. 4.4).   
Recent work has also led to the identification of the IL‐10R on the surface of Th17 cells 
(Huber et al., 2011); IL‐10 is able to bind its receptor and negatively regulate the secretion of IL‐
17 from Th17 cells (Chaudhry et al., 2011). We therefore sought to determine if IL‐10 mRNA 
expression during MAIDS progression was also increased. Whole splenic cells collected from 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groups of MAIDS‐4, MAIDS‐8, and MAIDS‐10 mice exhibited a significant (p ≤ 0.03) increase in 
IL‐10 mRNA production (Fig. 4.8C). In particular, levels of IL‐10 mRNA were high in whole 
splenic cells of MCMV retinitis‐susceptible MAIDS‐8 and MAIDS‐10 animals (Dix and Cousins, 
2004a; Dix et al., 1994). The increase in IL‐10 mRNA levels in whole splenic cells of MAIDS‐8 
mice and MAIDS‐10 mice correlated with the decrease in IL‐17 mRNA levels seen in CD4+ T cells 
during MAIDS progression (Fig. 4.4). 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Figure 4.8. SOCS‐1, SOCS‐3, and IL‐10 mRNA levels in whole splenic cells of C57BL/6 mice dur‐
ing the progression of MAIDS. (A) SOCS‐1 mRNA levels, (B) SOCS‐3 mRNA levels, and (C) IL‐10 
mRNA levels of whole splenic cells collected from groups of MAIDS‐4, MAIDS‐8, and MAIDS‐10 
mice (n = 5). Levels (fold‐change) of SOCS‐1 mRNA, SOCS‐3 mRNA, and IL‐10 mRNA were de‐
termined by quantitative RT‐PCR assay. Bars = Standard Error of the Mean of 2 independent 
experiments. Asterisks indicate statistical significance. 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4.2.8 SOCS‐1, SOCS‐3, and IL‐10 mRNA levels in MCMV‐infected eyes of MAIDS‐4 mice resis‐
tant to retinitis and MCMV‐infected eyes of MAIDS‐10 mice susceptible to retinitis  
To determine whether SOCS‐3 and IL‐10 production were also negatively influencing the 
expression of IL‐17 during the onset and progression of retinal necrosis in the eyes of MAIDS 
mice, MCMV‐infected and mock‐infected eyes from MAIDS‐4 and MAIDS‐10 mice were col‐
lected on days 3, 6, and 10 after MCMV subretinal infection and analyzed for SOCS‐3 and IL‐10 
mRNA expression. Additionally, mRNA levels of the required Th17 lineage differentiation factors 
SOCS‐1 and IL‐6 (Bettelli et al., 2007; Yoshimura et al., 2007) were also examined in MCMV‐
infected and mock‐infected eyes of MAIDS‐4 and MAIDS‐10 mice. While SOCS‐3 mRNA levels 
were indeed significantly (p ≤ 0.03) increased in MCMV‐infected eyes of MAIDS‐4 mice on day 6 
prior to the appearance of retinal necrosis on day 10 (Chien and Dix, 2012; Dix et al., 1994), 
MCMV‐infected eyes of MAIDS‐10 mice exhibited a far greater increase (p ≤ 0.007) in SOCS‐3 
mRNA levels when compared with mRNA levels of MCMV‐infected eyes of MAIDS‐4 mice on 
day 6 post‐infection (Fig. 4.9B). Similarly, IL‐10 mRNA levels in MCMV‐infected eyes of MAIDS‐
10 mice exhibited a dramatic 12‐fold and ~60‐fold (p ≤ 0.01) increase in IL‐10 mRNA on days 3 
and 6 post‐infection, respectively, when compared with mRNA levels in MCMV‐infected eyes of 
MAIDS‐4 mice (Fig. 4.9C). In comparison, SOCS‐1 (Fig. 4.9A) and IL‐6 (data not shown) mRNA 
levels mirrored those seen for SOCS‐3 and IL‐10, with mRNA levels of both molecules being sig‐
nificantly (p ≤ 0.03) increased in MCMV‐infected eyes of MAIDS‐10 mice when compared to 
MCMV‐infected eyes of MAIDS‐4 mice. It is noteworthy that increased mRNA levels of SOCS‐3 
and IL‐10 in the MCMV‐infected eyes of MAIDS‐10 mice preceded the decrease in IL‐17 mRNA 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levels seen in the eyes of these animals during retinitis development (Fig 4.6A), suggesting that 
SOCS‐3 and/or IL‐10 contribute to the downregulation of IL‐17 during ocular MCMV infection.  
 
 
Figure 4.9. SOCS‐1, SOCS‐3, and IL‐10 mRNA levels in MCMV‐infected eyes of MAIDS‐4 versus 
MCMV‐infected eyes of MAIDS‐10 mice. (A) SOCS‐1 mRNA levels, (B) SOCS‐3 mRNA levels, and 
(C) IL‐10 mRNA levels of MCMV‐infected eyes of MAIDS‐4 mice (dashed line) versus MCMV‐
infected eyes of MAIDS‐10 mice (solid line) collected at 3, 6, or 10 days after subretinal MCMV 
infection (n = 5). Levels (fold‐change) of SOCS‐1 mRNA, SOCS‐3 mRNA, and IL‐10 mRNA were 
determined by quantitative RT‐PCR assay. Bars = Standard Error of the Mean of 2 independent 
experiments. Asterisks indicate statistical significance. 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4.2.9 Effect of systemic MCMV infection on IL‐17 mRNA and protein levels in whole splenic 
cells and splenic CD4+ T cells of wildtype mice and IL‐10 ‐/‐ mice without MAIDS  
Because we demonstrated that IL‐10 mRNA levels were upregulated in whole splenic 
cells of MAIDS animals during the evolution of immunosuppression (Fig. 4.8C) as well as in the 
eyes of retinitis‐susceptible MAIDS animals following subretinal MCMV infection (Fig. 4.9C) and 
that the increase in IL‐10 mRNA is correlated with the decrease in IL‐17 mRNA observed in CD4+ 
T cells, we investigated whether knockout of IL‐10 would restore IL‐17 levels. Wild‐type mice 
without MAIDS and IL‐10 ‐/‐ mice without MAIDS were systemically infected with a sublethal 
dose of MCMV. Six days p.i., whole splenic cells and splenic CD4+ T cells were collected and 
analyzed for IL‐17 mRNA and protein levels by real‐time RT‐PCR assay and ELISA, respectively. 
Systemic MCMV infection of wild‐type mice resulted in a significant (p ≤ 0.03) decrease in IL‐17 
mRNA levels (Fig. 4.10A) confirming our previous findings (Fig 4.7A). However, while IL‐17 
mRNA levels were dampened in splenic cells of systemically infected IL‐10 ‐/‐ mice when com‐
pared to mock‐infected controls (Fig. 4.10A), IL‐17 protein levels were significantly (p ≤ 0.05) 
increased in whole splenic cells of these mice [12.28± 7.7 pg of IL‐17 per gram of spleen (wet 
weight)] when compared to systemically infected wild‐type mice [4.47± 3.5 pg of IL‐17 per gram 
of spleen (wet weight)] (Fig. 4.10B). The production of IL‐17 mRNA in splenic CD4+ T cells was 
significantly (p ≤ 0.03) reduced in both animal groups (Fig. 4.10C). However, IL‐17 mRNA levels 
were moderately increased, showing ~2‐fold higher levels of production in systemically infected 
IL‐10 ‐/‐ animals (Fig. 4.10D). These results suggest that IL‐10 knockout partially restored IL‐17 
levels during systemic MCMV infection. 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Figure 4.10. IL‐17 mRNA and protein levels in whole splenic cells and splenic CD4+ T cells of 
wild‐type mice and IL‐10 ‐/‐ mice following systemic MCMV infection. Comparison of IL‐17 
mRNA levels of (A) whole splenic cells, (C) and (D) splenic CD4+ T cells collected from wild‐type 
mice (n = 5) and IL‐10 ‐/‐ mice (n = 5) at 6 days following i.p. MCMV infection. Levels (fold‐
change) of IL‐17 mRNA were determined by quantitative RT‐PCR assay. Bars = Standard Error of 
the Mean of 2 independent experiments. Comparison of IL‐17 protein levels of (B) whole 
splenic cells collected from wild‐type mice (n = 5) and IL‐10 ‐/‐ mice (n = 5) at 10 days following 
i.p. MCMV infection. Protein levels were determined by ELISA. Bars = Standard Error of the 
Mean of 2 independent experiments. Asterisks indicate statistical significance. 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4.2.10 L‐17 mRNA and protein levels in whole splenic cells and eyes of wildtype MAIDS‐8 mice 
and IL‐10 ‐/‐ MAIDS‐8 mice following subretinal MCMV inoculation 
Since we demonstrated that systemic MCMV infection of IL‐10 ‐/‐ mice without MAIDS 
resulted in a partial restoration of IL‐17 mRNA and protein levels, we next wanted to determine 
whether subretinal MCMV infection of retinitis‐susceptible IL‐10 ‐/‐ MAIDS‐8 mice also resulted 
in partial recovery of IL‐17 mRNA and protein levels. Whole spleens and eyes were collected 
from wild‐type MAIDS‐8 mice and IL‐10 ‐/‐ MAIDS‐8 mice on day 10 after subretinal MCMV in‐
oculation and analyzed for IL‐17 mRNA and protein levels by real‐time RT‐PCR assay and ELISA, 
respectively. Results are shown in Figure 4.11. While IL‐17 mRNA levels did not increase in ei‐
ther whole splenic cells or whole eyes of IL‐10 ‐/‐ MAIDS‐8 mice following subretinal MCMV in‐
oculation (Fig. 4.11A and 4.11B), IL‐17 protein levels were consistently elevated, although not 
significantly, in both splenic cells and eyes of the IL‐10 ‐/‐ MAIDS‐8 animals (Fig. 4.11C and 
4.11D). Ocular tissues collected from IL‐10 ‐/‐ MAIDS‐8 mice and analyzed for IL‐17 protein via 
immunohistochemistry exhibited an enhancement in IL‐17 protein production when compared 
to MCMV‐infected eyes of wild‐type MAIDS‐8 mice (Fig. 4.12), although both groups remained 
equally susceptible to MCMV retinitis (85% frequency of retinitis, n = 7 mice/group). As ob‐
served during systemic MCMV infection, these results suggest that partial restoration of IL‐17 
was not sufficient to protect MAIDS mice against MCMV retinitis. 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Figure 4.11. IL‐17 mRNA and protein levels in whole splenic cells and MCMV‐infected eyes of 
wild‐type MAIDS‐8 and IL‐10 ‐/‐ MAIDS‐8 mice following subretinal MCMV infection. Com‐
parison of IL‐17 mRNA levels in (A) whole splenic cells and (B) MCMV‐infected eyes of groups of 
wild‐type MAIDS‐8 mice (n = 10) and IL‐10 ‐/‐ MAIDS‐8 mice (n = 10) at 10 days after subretinal 
MCMV infection. Levels (fold‐change) of IL‐17 mRNA were determined by quantitative RT‐PCR 
assay. Bars = Standard Error of the Mean of 1 experiment. Comparison of IL‐17 protein levels in 
(C) whole splenic cells and (D) MCMV‐infected eyes of groups of wild‐type MAIDS‐8 mice (n = 
10) and IL‐10 ‐/‐ MAIDS‐8 mice (n = 10) at 10 days after subretinal MCMV infection. Protein lev‐
els were determined by ELISA. Bars = Standard Error of the Mean of 1 experiment. All compari‐
sons showed no statistical significance. 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Figure 4.12. Detection of IL‐17 protein in MCMV‐infected eyes of wild‐type MAIDS‐8 mice and 
IL‐10 ‐/‐ MAIDS‐8 mice. Detection of IL‐17 in cells of representative retinal tissue sections col‐
lected from eyes of wild‐type MAIDS‐8 mice and IL‐10 ‐/‐ MAIDS‐8 mice at 10 days after 
subretinal MCMV infection or mock infection. Formalin‐fixed cytosections were reacted with 
anti‐IL‐17 antibody (red) or an isotype‐matched normal antibody (control). Nuclei were coun‐
terstained with DAPI (blue) (200X). 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5 DISCUSSION, FUTURE DIRECTIONS, AND SIGNIFICANCE 
5.1 Aim 1: Increased CD4+ T cell cytokines IL‐4 or IL‐10 dowregulate cellular immunity to 
increase susceptibility to experimental MCMV retinitis in mice with MAIDS 
Since its appearance as a major cause of vision loss and blindness within the United States 
nearly 30 years ago, AIDS‐related HCMV retinitis has become well characterized clinically and 
histologically (Dix and Cousins, 2004a; Holland, 1996). Despite many years of extensive clinical 
and laboratory investigation, however, a number of basic issues related to the virology, immu‐
nology, and pathogenesis of this sight‐threatening disease within the unique immunosuppres‐
sive environment of HIV infection and disease remain unresolved. Among these is a crisp and 
comprehensive understanding of the basic immunological changes that take place during retro‐
virus‐induced immunosuppression, especially those involved during loss of cellular immunity. 
Toward this end, we previously used our MAIDS model of MCMV retinitis to show that the per‐
forin‐mediated cytotoxic pathway is more important than the Fas/FasL‐mediated cytotoxic 
pathway in protection against MAIDS‐related MCMV retinitis (Dix et al., 2003a). We (Dix et al., 
2003a), and others (Loh et al., 2005), showed that loss of the perforin cytotoxic pathway results 
in an increased susceptibility to MCMV‐induced disease, including retinitis. Resistance to 
MCMV‐related disease, however, could be restored by immunotherapy with the Th1 cytokine 
IL‐2 (Dix et al., 1997b), a cytokine that has robust effects on cytotoxic T cell and natural killer 
(NK) cell functions (Smith, 1988). Unanswered in these investigations, however, was an under‐
standing of the precise mechanism(s) by which the perforin cytotoxic pathway is diminished 
during MAIDS in favor of the Fas/FasL cytotoxic pathway. These findings, coupled with the fact 
that progression of MAIDS is also associated with a prominent shift in cytokine production by 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CD4+ T cells from a Th1 profile to a Th2 profile (Dix and Cousins, 2004a) (Fig. 3.1) as seen during 
AIDS (Clerici and Shearer, 1993), lead to the attractive hypothesis that IL‐4 or IL‐10, both Th2 
cytokines that have been shown to be involved in downregulation of cellular immunity (Aung 
and Graham, 2000; Baschuk et al., 2007; Dix et al., 2003a; Kienzle et al., 2002; Kienzle et al., 
2005), play key roles in the pathogenesis of MAIDS‐related MCMV retinitis.  
Results reported herein suggest that this is not the case, and our hypothesis is incorrect. 
In fact, MCMV‐infected eyes of mice with MAIDS deficient in systemic IL‐4 or IL‐10 displayed a 
frequency of retinitis, a severity of retinitis, and intraocular amounts of virus equivalent to 
those found in MCMV‐infected eyes of wild‐type mice with MAIDS.  
That IL‐4 or IL‐10 should play a pivotal role in loss of cellular immunity during the patho‐
genesis of MAIDS‐related MCMV retinitis was a reasonable prediction. In addition to studies 
that have shown that increased IL‐4 or IL‐10 production during HIV infection results in de‐
creased cytotoxic CD8+ T‐cell activity against many viruses including HCMV (Elrefaei et al., 
2006; Elrefaei et al., 2007; Erard et al., 1994; Erard et al., 1993), numerous in vitro and in vivo 
studies have also noted an association between elevated levels of the Th2 cytokine IL‐4 and de‐
creased CD8+ T‐cell‐mediated cytotoxicity, all associated with an increase in FasL expression 
and a concomitant decrease in perforin and granzyme B expression. For example, Kienzle and 
colleagues (Kienzle et al., 2002; Kienzle et al., 2005) demonstrated that incubation of naïve 
mouse CD8+ T cells to high concentrations of IL‐4 resulted in a population of T cells with signifi‐
cantly lower expression of CD8 and reduced cytotoxic ability. Aung and coworkers (Aung and 
Graham, 2000) infected mice with an IL‐4‐expressing respiratory RSV recombinant and ob‐
served a subsequent increase in expression of FasL on CD4+ and CD8+ T cells coupled with al‐
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teration of the mechanism of CD8+ T‐cell cytotoxicity from a perforin‐mediated pathway to a 
favored Fas/FasL‐mediated pathway. Moreover, systemic treatment of mice with anti‐IL‐4 anti‐
body resulted in decreased morbidity following challenge with wild‐type RSV due to an en‐
hanced CD8+ cytotoxic response that lead to more effective virus clearance (Aung and Graham, 
2000). Similar findings were reported by Jackson and colleagues (Jackson et al., 2001) for 
mousepox virus infection. These workers observed suppressed CD8+ T‐cell cytotoxicity as well 
as suppressed NK‐cell cytotoxicity in mice infected with an IL‐4‐expressing mousepox virus, out‐
comes that resulted in increased virus‐induced mortality.   
Despite this convincing body of evidence, we did not observe increased resistance to 
MCMV retinitis in mice with MAIDS in the absence of functional IL‐4 or IL‐10 production as hy‐
pothesized. Without functional IL‐4 or IL‐10, two Th2 cytokines thought to dampen cellular im‐
munity during retrovirus‐induced immunosuppression (Elrefaei et al., 2006; Elrefaei et al., 2007; 
Erard et al., 1994; Erard et al., 1993; Furukawa et al., 2008), we predicted a resurgence in CD8+ 
T‐cell cytotoxicity that would provide protection against onset and progression of MCMV‐
induced retinal disease, possibly through stimulation of the perforin cytotoxic pathway associ‐
ated with a concomitant decline in the Fas/FasL cytotoxic pathway. Surprisingly, this was not 
the case. In fact, loss of IL‐4 or IL‐10 during MAIDS resulted in no significant change in splenic 
mRNA levels for perforin or granzyme B, two key molecules involved in the perforin cytotoxic 
pathway, when compared with wild‐type mice with MAIDS. More importantly, an increase in 
splenic mRNA levels for FasL was observed following loss of either IL‐4 or IL‐10 during MAIDS 
when compared with wild‐type mice with MAIDS. One explanation for these unexpected results 
is that while IL‐4 or IL‐10 may work individually to suppress cellular immunity during MAIDS, 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they also function collectively toward this end. Our findings suggest that loss of IL‐4 or IL‐10 
during MAIDS is an independent event that fails to affect production of the other Th2 cytokine. 
In fact, whole splenic cells from IL‐4 ‐/‐ MAIDS mice exhibited increased IL‐10 protein levels and 
whole splenic cells from IL‐10 ‐/‐ MAIDS mice exhibited equivalent IL‐4 protein levels to wild‐
type MAIDS mice, which potentially explains why these individual knockout MAIDS animals re‐
mained susceptible to retinitis. Thus, loss of one of these Th2 cytokines is not sufficient to re‐
duce the frequency or severity of MAIDS‐related MCMV retinitis in these animals.   
Another possible explanation for our unexpected findings may be that neither IL‐4 nor IL‐
10 play a role in governing susceptibility to MCMV retinitis. It is noteworthy that more recent 
findings from other laboratories have suggested that IL‐4 can indeed support development of 
cytotoxic T cells when incubated with highly purified primary T cells collected from lymph nodes 
of BALB/c mice (Miller et al., 1990; Trenn et al., 1988). Studies conducted by Bachmann and 
coworkers (Bachmann et al., 1995) also demonstrated that IL‐4 ‐/‐ C57BL/6 mice, when com‐
pared with wild‐type C57BL/6 mice, failed to exhibit changes in cytotoxic T‐cell responses when 
infected with lymphocytic choriomeningitis virus (LCMV) or vaccinia virus. These animals were 
also able to clear virus as a result of an effective cytotoxic T‐cell response. Additional studies 
conducted by Mo and colleagues (Mo et al., 1997) noted that CD8+ T cells collected from IL‐4 ‐
/‐ 129/J mice and wild‐type 129/J mice exhibited equivalent cytotoxic activity against Sendai 
virus infection. Similarly, IL‐10 has also been found to promote T cell development as well as 
CD8+ T cell cytotoxicity (Chen and Zlotnik, 1991; MacNeil et al., 1990; Santin et al., 2000). In 
fact, human pappillomavirus‐specific CD8+ T cells isolated from cervical cancer patients that 
were incubated with IL‐10 + IL‐2 exhibited increased cytotoxicity over that observed in CD8+ T 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cells incubated with IL‐2 alone (Santin et al., 2000). This increase CD8+ T cell cytotoxicity was 
correlated with increased perforin levels in the IL‐10 + IL‐2‐treated CD8+ T cells (Santin et al., 
2000).  While it is important to recognize that none of these studies investigated IL‐4 or IL‐10 
and cellular immunity in the context of retrovirus‐induced immunosuppression, these data indi‐
cate that perhaps neither IL‐4 nor IL‐10 decrease CD8+ T cell cytotoxicity to increase susceptibil‐
ity to MCMV retinitis.  
In summary, we show herein that mice with MAIDS deficient in either IL‐4 or IL‐10 do not 
develop resistance to MCMV retinitis as measured by amounts of intraocular infectious virus, 
frequency of retinitis, and severity of retinitis. Our findings therefore disprove our initial work‐
ing hypothesis that IL‐4 or IL‐10 are key Th2 cytokines that promote increased susceptibility to 
MAIDS‐related MCMV retinitis by dampening of cellular immunity, possibly by favoring the 
Fas/FasL cytotoxic pathway over the perforin cytotoxic pathway. However, IL‐4 and IL‐10 may 
work collectively with each other as well as with other host factors to create the unique in‐
traocular environment that allows for pathogenesis of MCMV retinitis.    
5.1.1 Future directions  
Future studies should address whether IL‐4 and IL‐10 work in a synergistic manner to 
govern susceptibility to MCMV‐related retinitis during MAIDS. One experimental approach to 
test this hypothesis would be to perform parallel studies using mice with MAIDS that suffer sys‐
temic loss in both IL‐4 and IL‐10 production. Unfortunately, double knockout mice exist only on 
a BALB/c background (Jackson Laboratory, Strain 004291), and MAIDS cannot be induced in 
BALB/c mice (Hartley et al., 1989). Alternatively, we could reduce systemic levels of both IL‐4 
and IL‐10 in mice with MAIDS using an antibody approach to neutralize their functions. How‐
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ever, studies to reduce systemic levels of only IL‐4 in mice with MAIDS using anti‐IL‐4 antibody 
proved to be ineffective, resulting in only ~50% reduction in splenic levels of IL‐4 mRNA and 
protein (Fig. 3.2).  Lastly, future studies of CD8+ T cell cytotoxicity utilizing flow cytometry‐
based killing assays would be a nice addition to this study in order to show that CD8+ T cell‐
mediated cytotoxic activities in the IL‐4 ‐/‐ MAIDS mice and the IL‐10 ‐/‐ MAIDS mice are 
equivalent to the CD8+ T cell‐mediated cytotoxic activities seen in wild‐type MAIDS mice and 
that this loss in cell‐mediated cytotoxicity is correlated with increased FasL mRNA expression in 
whole splenic cells of the knockout MAIDS animals. 
 
5.2 Aim 2: Increased production of IL‐17 from CD4+ Th17 cell contributes to the pathogene‐
sis of experimental MCMV retinitis in mice with MAIDS 
The aims of the present study were to determine the fate of IL‐17 during HIV infection, 
and to determine whether IL‐17 contributes to the pathogenesis of AIDS‐related HCMV retinitis 
through the use of a clinically relevant mouse model of MAIDS‐related MCMV retinitis. 
Whereas IL‐17 expression was detected within the spleen and eyes of healthy mice, IL‐17 mRNA 
and protein were increased systemically during MAIDS progression when compared to healthy 
mice. However, MCMV‐infected eyes of retinitis‐susceptible MAIDS‐10 mice, but not MCMV‐
infected eyes of retinitis‐resistant MAIDS‐4 mice, exhibited a significant decrease in IL‐17 mRNA 
expression and dampened IL‐17 protein levels. IL‐17 mRNA was also decreased in whole splenic 
cells as well as in splenic CD4+ T cells of healthy mice and MAIDS animals upon systemic MCMV 
infection. This decrease was associated with increased levels of SOCS‐3 and IL‐10 mRNAs during 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MCMV infection. However, knockout of IL‐10 in MAIDS mice only partially restored IL‐17 levels 
and failed to protect mice against MCMV retinitis.   
 
5.2.1 IL‐17 production in splenic cells and eyes of C57BL/6 mice during health 
IL‐17 was detected at low levels in the spleens of healthy mice, an observation consis‐
tent with that of Brenchley and coworkers (Brenchley et al., 2008) who detected low levels of 
IL‐17‐expressing CD4+ T cells in the peripheral blood of healthy human patients. IL‐17 was also 
detected in cells of the neurosensory retina and the photoreceptor layer of healthy mice, but IL‐
17 production in the eye was lower than that in the spleen.  Further investigation determined 
that both cell types that comprise the photoreceptor layer, rod cells and cone cells, constitu‐
tively express IL‐17 during health. To our knowledge, ours is the first study to identify resident 
IL‐17‐expressing cells within the ocular compartment of healthy mice. We postulate that in ad‐
dition to retinal photoreceptors cells, retinal pericytes and/or microglia also produce IL‐17 in 
the healthy mouse eye due to their distribution within the neurosensory retina and their ability 
to secrete inflammatory cytokines (Chen et al., 2002; Crane and Liversidge, 2008; Guillemin and 
Brew, 2004). Future experiments should be focused on determining the cellular source of IL‐17 
production in the neurosensory retina of healthy mice.  
 
5.2.2 IL‐17 production in splenic cells and eyes of C57BL/6 mice during progression of MAIDS 
Previous studies on IL‐17 production during HIV/AIDS remain discordant (Brenchley et 
al., 2008; Maek et al., 2007; Yue et al., 2008). Our findings using mice with MAIDS to determine 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the fate of IL‐17 during the progression of retrovirus‐induced immunosuppression agreed with 
previous studies (Maek et al., 2007; Yue et al., 2008) showing IL‐17 production was increased in 
patients during HIV infection. We observed a significant increase in IL‐17 mRNA and protein 
levels in whole splenic cell populations as well as in mRNA in whole eyes when compared to 
healthy age‐matched controls. However, unlike whole splenic cells, MAIDS progression was also 
associated with a concomitant decrease in IL‐17 mRNA levels in splenic CD4+ T cells, a finding 
that was in agreement with Brenchley and coworkers (Brenchley et al., 2008) observations in 
HIV‐infected individuals. Other known cellular sources of IL‐17, splenic macrophages and 
splenic Gr‐1‐expressing cells (neutrophils), contributed little to the overall IL‐17 mRNA levels 
observed during MAIDS progression suggesting that there is not one sole source of IL‐17 pro‐
duction by these animals. Thus, CD4+ T cells, macrophages, and Gr‐1‐expressing cells (neutro‐
phils) in combination with other known sources of IL‐17 including natural killer T cells (NKTs), 
CD8+ T cells, and gamma‐delta (γδ) T cells (Gaffen, 2009; Iwakura et al., 2011; Rachitskaya et al., 
2008) might all collectively contribute to the overall increase of IL‐17 observed during MAIDS. 
The contributions of each of the other known cellular sources of IL‐17, including CD8+ T cells, 
NKT cells, and γδ T cells, to the increased levels of IL‐17 observed in whole splenic cells of 
MAIDS mice during retrovirus‐induced immunosuppression progression should be assessed in 
future studies.  
 
5.2.3 IL‐17 production and susceptibility to MCMV retinitis during MAIDS 
Intraocular IL‐17 production has been associated with uveitis, an inflammatory disease 
of the retina and uvea. Disease etiology is autoimmune in nature, with patients exhibiting im‐
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mune responses to ocular antigens including retinal arrestin and interphotoreceptor retinoid‐
binding protein (Caspi, 2010). EAU in mice has defined with some precision the effector cells 
involved in retinal and uveal tissue destruction during disease pathogenesis (Caspi, 2010; Luger 
and Caspi, 2008; Luger et al., 2008). Originally thought to be solely a Th1‐mediated disease, 
uveitis is also induced through the actions of Th17 cells and IL‐17 secretion (Caspi, 2010; Luger 
and Caspi, 2008; Luger et al., 2008). Neutralization of IL‐17 through passive transfer of anti‐IL‐
17 antibody has been shown to mitigate EAU severity significantly (Amadi‐Obi et al., 2007; 
Luger et al., 2008; Peng et al., 2007). Conversely, adoptive transfer of retinal antigen‐specific 
Th17 cells has been shown to induce EAU development in naïve mice (Luger et al., 2008; Peng 
et al., 2007).   
Because IL‐17 is involved in uveitis pathogenesis, we sought to determine whether the 
increase in IL‐17 levels seen in mice with MAIDS played a role in susceptibility to MCMV retini‐
tis. Whereas MAIDS‐4 mice resistant to retinitis did not exhibit changes in IL‐17 mRNA levels 
following subretinal MCMV inoculation when compared to mock‐infected controls, MCMV‐
infected eyes of MAIDS‐10 mice susceptible to retinitis exhibited a significant decrease in IL‐17 
mRNA levels. Additionally, ocular IL‐17 protein levels and patterns of IL‐17 immunohistochemi‐
cal staining were dampened in MCMV‐infected eyes of these retinitis‐susceptible animals when 
compared to mock‐infected eyes. We therefore conclude that IL‐17 plays no direct role in in‐
creased susceptibility to MCMV retinitis during MAIDS. It is possible, however, that IL‐17 may 
act indirectly to increase susceptibility to MCMV retinitis or may play a protective role in MCMV 
retinitis development in MAIDS mice. 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5.2.4 IL‐17 production in splenic CD4+ T cells of healthy mice and MAIDS mice following sys‐
temic MCMV infection 
The surprising observation of significantly reduced IL‐17 mRNA and dampened protein 
levels during ocular MCMV infection of MAIDS‐10 mice led us to investigate whether MCMV 
actually downregulated IL‐17 production from CD4+ T cells systemically. In agreement with this 
hypothesis was our finding that systemic MCMV infection resulted in a significant reduction of 
IL‐17 mRNA levels in whole splenic cells and splenic CD4+ T cells from groups of healthy mice, 
MAIDS‐4 mice, and MAIDS‐10 mice. Moreover, experiments using UV‐inactivated virus sug‐
gested that active MCMV infection was not an absolute requirement for reduction of IL‐17 
mRNA in CD4+ T cells, although productive MCMV replication did result in a more profound de‐
crease in IL‐17 mRNA levels. Taken together, these results suggest that a structural MCMV pro‐
tein(s) as well as one or more virus‐induced proteins during virus replication might work in con‐
cert to contribute to the downregulation of IL‐17 through the upregulation of IL‐10 and SOCS‐3 
(Fig. 5.1).   
It is interesting to note that a structural protein of HCMV, the pp65 tegument protein, 
has been shown to alter the host immune response early during infection by blocking the inter‐
feron response and inhibiting the activity of NK cells through direct interaction with its receptor 
(Arnon et al., 2005; Kalejta, 2008; Miller‐Kittrell and Sparer, 2009). Since MCMV encodes a pp65 
homolog, M83/84 (Cranmer et al., 1996; Kattenhorn et al., 2004), it is possible that the M83/84 
tegument protein of MCMV might also serve to downregulate IL‐17 production in MCMV‐
infected cells. The action of these tegument proteins leads to decreased T cell activation and 
ultimately a decreased immune response that favors viral replication and persistence.  It is pos‐
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sible then that during MCMV infection, the actions of tegument proteins indirectly leads to the 
decreased production of inflammatory cytokines including IL‐17 from CD4+ T cells, macro‐
phages, and neutrophils (Gr‐1‐expressing cells).     
Structural HCMV glycoproteins also exhibit immune evasion properties.  MCMV gp34, 
gp40, and gp48 are functional homologs of HCMV glycoproteins encoded by viral genes US2, 
US3, and US11, respectively (Kavanagh et al., 2001).  These MCMV viral glycoproteins decrease 
MHC I protein expression on virus‐infected cells (Kattenhorn et al., 2004; Kavanagh et al., 2001; 
Loewendorf and Benedict, 2010; Loewendorf et al., 2011; Mocarski, 2002; Wagner et al., 2002), 
leading to decreased CD4+ T cell and CD8+ T cell activation. In addition, the MCMV m155 pro‐
tein inhibits expression of the CD4+ T cell and CD8+ T cell stimulator protein CD40 in virus‐
infected monocytes/macrophages as well as in virus‐infected dendritic cells (Elgueta et al., 
2009; Loewendorf et al., 2011; Ma and Clark, 2009). The action of these viral glycoproteins to 
decease the activation of CD4+ T cells might account for the reduction in IL‐17 production from 
CD4+ T cells that was observed during MCMV infection of healthy mice and mice with MAIDS.  
Future experiments should be done to investigate the exact role of these viral proteins in IL‐17 
downregulation during systemic and ocular MCMV infection. Selective overexpression or 
knockdown of MCMV immunoregulatory tegument proteins m83/84 and/or MCMV immune 
evasion viral glycoproteins utilizing a bacterial artificial chromosome (BAC) system would reveal 
their direct involvement in downregulating IL‐17 during systemic MCMV infection and whether 
the downregulation of IL‐17 by MCMV is directly correlated with increased IL‐10 and SOCS‐3 
levels. 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In addition to MCMV viral tegument and glycoproteins contributing to the downregula‐
tion in IL‐17 during infection, cytokine secretion from infected, activated macrophages may also 
contribute to the downregulation of IL‐17 during systemic infection of mice with both actively 
replicating MCMV as well as UV‐inactivated MCMV. Both HCMV and MCMV infection induce 
the production of immunosuppressive IL‐10 (Humphreys et al., 2007; Redpath et al., 1999) in 
infected macrophages as well as in CD4+ T cells. We confirmed the upregulation of IL‐10 in 
splenic CD4+ T cells of MAIDS‐10 mice during MCMV infection (data not shown).  In addition, IL‐
10 secretion from anti‐inflammatory M2 macrophages promotes wound healing as well as an‐
giogenesis, which consequently leads to the reduction of pro‐inflammatory cytokines (Cassetta 
et al., 2011; Gordon, 2003; Mosser and Edwards, 2008; Sunderkotter et al., 1994).  We believe 
that an upregulation of IL‐10 from M2 macrophages as well as CD4+ T cells during MCMV infec‐
tion as well as during UV‐inactivated MCMV infection may potentially contribute to the down‐
regulation of IL‐17 we observed in both our healthy and MAIDS mice. However, MCMV and 
HCMV have been also noted to induce the secretion of pro‐inflammatory cytokines from 
macrophages including TNF‐α, IL‐1β, and IL‐6 during infection (Iwamoto et al., 1990; Pulliam et 
al., 1995; Smith et al., 1992; Vliegen et al., 2004). Pro‐inflammatory M1 macrophage cytokines 
have been associated with increased IL‐17 production and vise versa (Jovanovic et al., 1998; 
Sutton et al., 2006). Based on our results from these studies, we believe that acute MCMV in‐
fection leads to the induction of M2 macrophages as well as CD4+ T cells that secrete IL‐10, 
which ultimately contributes to the downregulation in IL‐17 that we observed in whole splenic 
cells as well as splenic CD4+ T cells of systemically infected healthy and MAIDS mice. 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5.2.5 Proposed mechanism of IL‐17 downregulation during MCMV infection 
The observation that IL‐17 was decreased in CD4+ T cells during MAIDS progression as 
well as during ocular and systemic infection of retinitis‐susceptible MAIDS animals led us to in‐
vestigate possible mechanisms by which retrovirus‐induced immunosuppression might down‐
regulate IL‐17 production by CD4+ T cells. Recent studies have implicated both SOCS‐3 and IL‐10 
as negative regulators of IL‐17 secretion (Chaudhry et al., 2011; Gu et al., 2008; Huber et al., 
2011). It is therefore possible that increases in one or both of these proteins would cause the 
IL‐17 mRNA decrease observed by us in CD4+ T cells during MAIDS progression. SOCS‐3 is in‐
duced by cytokine signaling (Yoshimura et al., 2007) and negatively regulates Th17 cell differen‐
tiation by suppressing STAT3 activation of IL‐6 and IL‐23 receptors on Th17 cells (Chen et al., 
2006; Yoshimura et al., 2007). Additionally, SOCS‐3 levels are increased during HIV infection 
(Akhtar and Benveniste, 2011; Akhtar et al., 2010). We have shown that SOCS‐3 mRNA levels 
were significantly increased during retrovirus‐induced immunosuppression, with mRNA levels 
peaking in MAIDS‐10 mice when most susceptible to MCMV retinitis (Dix and Cousins, 2004a; 
Dix et al., 1994). Importantly, the increase in SOCS‐3 mRNA levels correlated with the decrease 
in IL‐17 mRNA levels seen in CD4+ T cells during MAIDS progression, suggesting a potential ex‐
planation for the observed downregulation in IL‐17 mRNA from CD4+ T cells during MAIDS pro‐
gression. 
While little is currently known about the potential induction of SOCS‐3 or SOCS‐1 during 
MCMV infection, a number of viruses including influenza, respiratory syncytial virus (RSV), HIV, 
and HSV‐1 exploit SOCS proteins, activating them in order to evade the host cell immune re‐
sponse (Akhtar and Benveniste, 2011; Frey et al., 2009; Yokota et al., 2005). We propose that 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MCMV acts in a similar manner to upregulate SOCS‐1 and SOCS‐3 proteins. While we observed 
increases in both SOCS‐1 and SOCS‐3 mRNA levels in the MCMV‐infected eyes of MAIDS‐4 and 
MAIDS‐10 mice, levels were far higher in the MCMV‐infected eyes of MAIDS‐10 mice that were 
susceptible to retinitis. Importantly, the increase in ocular SOCS‐3 mRNA levels preceded the 
decrease in IL‐17 mRNA seen in MCMV‐infected eyes of MAIDS‐10 mice.  In addition, the in‐
crease in SOCS‐3 mRNA on day 6 was approximately 10‐fold higher than the SOCS‐1 mRNA lev‐
els we observed in the MCMV‐infected eyes of MAIDS‐10 mice. These results indicate to us that 
while positive regulator of Th17 cell differentiation SOCS‐1 was significantly increased during 
the development of MCMV retinitis in MAIDS‐10 mice, these mRNA levels were not high 
enough to overcome the dramatic increase in mRNA that we observed in the Th17 cell negative 
regulator SOCS‐3. Protein levels for both SOS‐1 and SOCS‐3 determined by Dr Hsin Chein in our 
laboratory (unpublished data) mirrored our mRNA results, where both SOCS‐1 and SOCS‐3 pro‐
tein levels were significantly increased in the MCMV‐infected eyes of MAIDS‐10 mice when 
compared to MCMV‐infected eyes of MAIDS‐4 mice. However, protein levels in MCMV‐infected 
eyes of both MAIDS‐4 and MAIDS‐10 mice peaked on day 10.  The highest levels of SOCS‐3 pro‐
tein on day 10 correlated with the significant downregulation of IL‐17 we observed the in 
MCMV‐infected eyes of MAIDS‐10 mice.  This suggests that in addition to the action of its viral 
tegument proteins and glycoproteins, MCMV may also upregulate SOCS‐3 for efficient viral rep‐
lication or for evasion of the host immune response, which, in turn, results in the downregula‐
tion of IL‐17.   
IL‐10 is an anti‐inflammatory cytokine secreted by numerous immune cells, and it is able 
to regulate IL‐17 secretion by binding to its receptor on Th17 cells (Chaudhry et al., 2011; 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Couper et al., 2008; Huber et al., 2011). In our study, we demonstrated that IL‐10 mRNA levels 
were significantly increased during MAIDS progression, and peaked at 10 weeks after retrovi‐
rus‐induced immunosuppression when animals were susceptible to MCMV retinitis (Dix and 
Cousins, 2004a; Dix et al., 1994). Similar to SOCS‐3, the increase in IL‐10 mRNA levels correlated 
with the decrease in IL‐17 mRNA levels seen in CD4+ T cells during MAIDS progression. 
Systemic MCMV infection also induces expression of IL‐10 in both CD4+ T cells as well as 
in MCMV‐infected macrophages (Humphreys et al., 2007; Redpath et al., 1999). Increased pro‐
duction of IL‐10 during MCMV infection leads to reduction of MHC class II on virus‐infected cells 
and subsequently a decreased host response (Redpath et al., 1999). In agreement with these 
studies, we observed a significant increase in IL‐10 mRNA levels in MCMV‐infected eyes of 
MAIDS‐10 mice that were susceptible to MCMV retinitis. As IL‐10 mRNA levels increased during 
MCMV retinitis development, IL‐17 mRNA levels decreased. It is therefore possible that MCMV 
infection orchestrates the downregulation of IL‐17 through the induction of IL‐10 along with 
SOCS‐3.  
Although systemic MCMV infection of IL‐10 ‐/‐ mice without MAIDS resulted in an in‐
crease in IL‐17 mRNA and protein in whole splenic cells and an increase in IL‐17 mRNA expres‐
sion levels in CD4+ T cells, and subretinal MCMV infection of MAIDS‐8 IL‐10 ‐/‐ mice led to ele‐
vated levels of IL‐17 protein in whole splenic cells and MCMV‐infected eyes, this partial recov‐
ery was not sufficient to protect MAIDS‐8 mice against MCMV retinitis development. These re‐
sults suggest that knockout of IL‐10 results only in a partial restoration of IL‐17 expression lev‐
els. Thus, other proteins, such as SOCS‐3 and/or MCMV viral proteins, contribute to the down‐
regulation of IL‐17 during MCMV infection. 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In conclusion, we have demonstrated that IL‐17 plays no direct role in the pathogenesis 
of MAIDS‐related MCMV retinitis. Remarkably, however, systemic MCMV infection of mice with 
MAIDS resulted in the downregulation of IL‐17 production from CD4+ T cells, possibly through 
the actions of MCMV viral proteins and/or the upregulation of SOCS‐3 and IL‐10 mRNA produc‐
tion (Fig. 5.1) during infection. SOCS‐3 and IL‐10 may work in a synergistic manner to downregu‐
late IL‐17 from CD4+ T cells, although the direct role of SOCS‐3 in downregulation of IL‐17 dur‐
ing MCMV infection remains unclear. Lastly, while partial restoration of IL‐17 through knockout 
of IL‐10 did not reduce the frequency and/or severity of MCMV retinitis in MAIDS animals, it 
remains to be determined whether full restoration of IL‐17 from Th17 cells during MAIDS plays 
a protective role in resistance to MCMV retinitis. 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Figure 5.1. Proposed mechanism for downregulation of IL‐17 in Th17 cells by MCMV. MCMV 
infection stimulates IL‐10 production during health and retrovirus‐induced immunosuppression. 
IL‐10 binds to its receptor on Th17 cells that induces activation of Janus kinase‐1 (Jak1) and ty‐
rosine kinase‐2 (Tyk2) that leads to the phosphorylation of signal transducer and activator of 
transcription‐3 (STAT‐3). Phosphorylated STAT‐3 translocates to the nucleus where it upregu‐
lates SOCS‐3 transcription that results in an increase in SOCS‐3 protein intracellularly and ulti‐
mately inhibition of STAT‐3 phosphorylation at the IL‐6 and IL‐23 receptors on Th17 cells. This 
inhibition culminates in decreased production of IL‐17 by Th17 cells. [Adapted from (Sabat et 
al., 2010; Yoshimura et al., 2007)] 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5.2.6 Future directions 
 While the results obtained from this study indicated that IL‐17 does not play a direct 
role in MCMV‐related retinitis pathogenesis, IL‐17 may play an indirect role in governing sus‐
ceptibility to MCMV retinitis development in MAIDS mice.  For example, the progression of 
MAIDS results in increased numbers of neutrophils and macrophages systemically (Mosier et 
al., 1985), and it is possible that the increased systemic IL‐17 we observed during the progres‐
sion of retrovirus‐induced immunosuppression, from multiple cellular sources, leads to the ac‐
tivation of these neutrophils and macrophages (Annunziato et al., 2010; Iwakura et al., 2011; 
Stockinger et al., 2007; Weaver et al., 2007).  IL‐17‐activated macrophages and neutrophils in 
MAIDS mice may then perfuse into the tissues, including the eyes of MAIDS animals.  This influx 
of activated macrophages and neutrophils into the eyes of MAIDS mice during subretinal 
MCMV infection caused by elevated IL‐17 levels could thus contribute to retinitis development 
through the production of pro‐inflammatory cytokines (i.e., TNF‐α) by these cells (Chien and 
Dix, 2012; Dix and Cousins, 2004b).  The use of IL‐17A ‐/‐ mice in future experiments, through a 
collaboration with Dr. Chen Dong (Martin‐Orozco et al., 2009), would allow us to decipher the 
exact role of IL‐17 during the development of MAIDS as well as during MCMV‐retinitis devel‐
opment in MAIDS animals.   
On the other hand, because we observed decreased in IL‐17 levels during MCMV infec‐
tion of retinitis‐susceptible MAIDS‐10 mice, it is possible that IL‐17 is important in mitigating 
rather than exacerbating MCMV‐related retinal disease development.  Future studies should 
investigate whether or not treatment of retinitis‐susceptible MAIDS mice with recombinant IL‐
17 prior to subretinal MCMV infection provides protection against MCMV‐related retinitis de‐
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velopment.  However, ocular administration of recombinant IL‐17 of retinitis‐susceptible MAIDS 
mice during subretinal MCMV infection may be necessary in order to determine the potential 
protective properties of IL‐17 during MCMV retinitis development.  Additionally, if knockdown 
of the tegument proteins and/or the immune evasion viral glycoproteins leads to the upregula‐
tion of IL‐17 during infection, this would provide an alternative approach for us to determine 
whether IL‐17 plays a protective role in MCMV retinitis pathogenesis.      
Due to the current unavailability of IL‐17A ‐/‐ mice, we aimed to better decipher the role 
of IL‐17 during MCMV retinitis development in MAIDS mice by altering an IL‐17 negative regula‐
tor in this current study, IL‐10, that was upregulated systemically during MAIDS progression as 
well as in during ocular MCMV infection of retinitis‐susceptible MAIDS mice.  Additionally, 
SOCS‐3 was also upregulated in both whole splenic cells during the progression of MAIDS and in 
MCMV‐infected eyes of MAIDS‐10 mice. We believe that the loss of SOCS‐3 would partially re‐
store IL‐17 levels in a similar fashion to what we observed in our IL‐10 ‐/‐ mice. However, 
knockdown of SOCS‐3 in mice is lethal (Robb et al., 2005; Takahashi et al., 2003).  SOCS‐3 condi‐
tional knockouts, mice devoid of SOCS‐3 protein production in particular tissues, could be util‐
ized, but mice lacking SOCS‐3 protein in the ocular tissues are not commercially available.  Addi‐
tionally, SOCS‐3 antibody treatment could be utilized; however, when we utilized antibody 
treatment to downregulate IL‐4 in our MAIDS animals, we only obtained a 50% reduction in IL‐4 
protein (Aim 1, Fig. 3.2).  Thus, SOCS‐3 antibody treatment of MAIDS mice does not present a 
practical model to decipher the role of IL‐17 in MCMV‐related retinitis. We could also consider 
developing mice that overexpress either SOCS‐3 or IL‐10 as well as both SOCS‐3 and IL‐10 in 
ocular tissues in order to determine the degree to which each of these cytokines downregulates 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IL‐17 during infection. Based on our results from this study utilizing IL‐10 ‐/‐ MAIDS mice, we 
believe that in addition to IL‐10, SOCS‐3 contributes to the downregulation of IL‐17 during 
MCMV infection, and that the loss of both of SOCS‐3 and IL‐10 is essential for fully restoring IL‐
17 levels in Th17 cells during systemic and ocular MCMV infection. 
   
5.3 Significance 
Overall, the results from these studies furthers our basic understanding of the patho‐
genesis of AIDS‐related HCMV retinitis as well as our understanding of the immunobiology of 
HCMV.  Analysis of the host cell CD4+ T cell cytokines IL‐17, IL‐4, and IL‐10 during retrovirus‐
induced immunosuppression as well as during the development of retinal disease provide evi‐
dence for their collaborative involvement in disease development (IL‐4 and IL‐10) as well as 
their potential protective capabilities (IL‐17).  Further study of the mechanism of action of these 
cytokines will help to direct the development of novel drug targets to manage existing HCMV 
retinitis and/or prevent its development in HIV/AIDS patients. 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